Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 1 of 98 12 Dec 2022 
 Title Page  
Protocol  Title:  A Phase 1, Randomized, Placebo -controlled, Double -blind, 
Multiple Ascending Dose Study to Investigate Safety, Tolerability, 
and Pharmacokinetics of Oral Doses of TCK -276 in Patients with 
Rheumatoid Arthritis  
Brief  Title:  A Study to Investigate Safety, Tolerability, and Pharmacokinetics 
of Oral Doses of TCK -276 in Patients with Rheumatoid Arthritis  
Compound : TCK -276 
Indication:  Rheumatoid arthritis  
Study Sponsor:  Teijin Ameri ca, Inc.  
1 Harbor Drive, Suite 200, Sausalito, CA, USA , 94965  
Protocol  Number:  TCK-276-102 
Study Phase:  1 
Regulatory Agency 
Identifying 
Number :  
Version:  3.0 
Amendment 
Number:  Amendment 2 
Amendment Scope ; 
Region/Country 
Identifier  Global  
Approval Date : Final , 12 Dec 2022  
Date and Version of 
Previous Protocol:  ; Version: 2.0 
 
Confidentiality Statement  
This document contains confidential information of Teijin America, Inc. Do not copy or distribute without written 
permission from the Sponsor.  
  

Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 2 of 98 12 Dec 2022 
 Sponsor Signatory:  
 
 
Medical Monitor Name and Contact Information : 
 
  

Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 5 of 98 12 Dec 2022 
 Table of Contents  
Title Page  ................................ ................................ ................................ ................................ ........  1 
Protocol Amendment Summary of Changes Table  ................................ ................................ ........  3 
Table of Contents  ................................ ................................ ................................ ............................  5 
List of Tables  ................................ ................................ ................................ ................................ .. 9 
List of Figures  ................................ ................................ ................................ ................................ . 9 
1 Protocol Summary  ................................ ................................ ................................ ..................  10 
1.1 Synopsis  ................................ ................................ ................................ ..............................  10 
1.2 Schema  ................................ ................................ ................................ ...............................  17 
1.3 Schedule of Ac tivities  ................................ ................................ ................................ .........  18 
2 Introduction ................................ ................................ ................................ .............................  21 
2.1 Study Rationale  ................................ ................................ ................................ ..................  21 
2.2 Back ground ................................ ................................ ................................ .........................  22 
2.2.1  Summary of Findings from Non -clinical Studies with Potential Clinical Relevance  .... 22 
2.2.2  Summary of Findings from Previous Clinical Studies  ................................ ...................  24 
2.3 Benefit/Risk Assessment  ................................ ................................ ................................ .... 25 
2.3.1  Risk Assessment  ................................ ................................ ................................ .............  25 
2.3.2  Benefit Assessment  ................................ ................................ ................................ .........  29 
2.3.3  Overall Benefit/Risk Conclusion  ................................ ................................ ....................  29 
3 Objectives and Endpoints  ................................ ................................ ................................ ....... 30 
4 Study Design  ................................ ................................ ................................ ...........................  33 
4.1 Overall Design  ................................ ................................ ................................ ....................  33 
4.2 Scientific Rationale for Study Design  ................................ ................................ ................  36 
4.3 Justification for Dose  ................................ ................................ ................................ ..........  36 
4.4 End of Study Definition ................................ ................................ ................................ ...... 37 
5 Study Population  ................................ ................................ ................................ .....................  37 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................  37 
5.2 Exclusion Criteria  ................................ ................................ ................................ ...............  39 
5.3 Lifestyle Considerations  ................................ ................................ ................................ ..... 42 
5.3.1  Meals and Dietary Restrictions  ................................ ................................ ......................  42 
5.3.2  Caffeine, Alcohol, and Tobacco  ................................ ................................ ......................  42 
5.4 Screen Failures  ................................ ................................ ................................ ...................  42 
Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 6 of 98 12 Dec 2022 
 5.4.1  Screening and Enrollment Log and Patient Identification Numbers  ..............................  43 
6 Study Intervention(s) and Concomitant Therapy  ................................ ................................ ... 43 
6.1 Study Intervention(s) Administered  ................................ ................................ ...................  43 
6.2 Preparation, Handling, Storage, and Accountability  ................................ ..........................  44 
6.3 Measures to Minimize Bias: Randomiza tion and Blinding  ................................ ................  45 
6.4 Study Intervention Compliance  ................................ ................................ ..........................  46 
6.5 Dose Modification  ................................ ................................ ................................ ..............  46 
6.6 Continued Access to Study Intervention After the End of the Study  ................................ . 46 
6.7 Treatment of Overdose  ................................ ................................ ................................ ....... 47 
6.8 Concomitant Therapy  ................................ ................................ ................................ .........  47 
6.8.1  Permitted Medications  ................................ ................................ ................................ .... 47 
6.8.2  Prohibited Medications  ................................ ................................ ................................ ... 48 
6.8.2.1  Caution  ................................ ................................ ................................ ........................  48 
7 Discontinuation of Study Intervention and Patient Discontinuation  ................................ ...... 48 
7.1 Discontinuation of Study Intervention  ................................ ................................ ...............  48 
7.1.1  Overall Study Stopping Criteria  ................................ ................................ .....................  49 
7.1.2  Dose Escalation  ................................ ................................ ................................ ..............  50 
7.2 Patient Discontinuation/Withdrawal from the Study  ................................ ..........................  51 
7.3 Lost to Follow -Up ................................ ................................ ................................ ..............  53 
8 Study Assessments and Procedures  ................................ ................................ ........................  54 
8.1 Administrative Procedures  ................................ ................................ ................................ . 55 
8.1.1  Informed Consent  ................................ ................................ ................................ ...........  55 
8.1.2  Patient Identification Card  ................................ ................................ ..............................  55 
8.1.3  Calibration of Equipment  ................................ ................................ ...............................  55 
8.2 Screening and Eligibility Assessments  ................................ ................................ ...............  55 
8.2.1  Eligibility Criteria  ................................ ................................ ................................ ...........  55 
8.2.2  Demography and Other Baseline Information  ................................ ...............................  56 
8.2.3  Medical History  ................................ ................................ ................................ ..............  56 
8.2.4  Prior and Concomitant Medications Review  ................................ ................................ .. 57 
8.2.5  Screening Assessments  ................................ ................................ ................................ ... 57 
8.3 Safety Assessments  ................................ ................................ ................................ .............  58 
8.3.1  Physical Examinations  ................................ ................................ ................................ .... 58 
8.3.2  Vital Signs  ................................ ................................ ................................ ......................  58 
8.3.3  Electrocardiograms  ................................ ................................ ................................ .........  59 
8.3.4  Cardiac Telemetry  ................................ ................................ ................................ ...........  59 
Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 7 of 98 12 Dec 2022 
 8.3.5  Clinical Safety Laboratory Tests  ................................ ................................ ....................  59 
8.3.6  Pregnancy Testing  ................................ ................................ ................................ ...........  60 
8.4 Adverse Events, Serious Adverse Events, and Other Safety Reporting  .............................  60 
8.4.1  Time Period and Frequency for Collecting Adverse Events and Serious Adverse Events 
Information  ................................ ................................ ................................ .....................  61 
8.4.2  Method of Detecting Adverse Events and Serious Adverse Events  ...............................  61 
8.4.3  Follow -up of Adverse Events and Serious Adverse Events  ................................ ...........  61 
8.4.4  Regulatory Reporting Requirements for Serious Adverse Event  ................................ ... 62 
8.4.5  Pregnancy  ................................ ................................ ................................ .......................  62 
8.4.6  Adverse events of Special Interest  ................................ ................................ .................  63 
8.5 Pharmacokinetics  ................................ ................................ ................................ ................  64 
8.5.1  Blood Sample Collection  ................................ ................................ ................................  64 
8.5.2  Urine Sample Collection  ................................ ................................ ................................  64 
8.6 Exploratory Assessments  ................................ ................................ ................................ .... 64 
8.7 Genetics  ................................ ................................ ................................ ..............................  65 
8.8 Biomarkers  ................................ ................................ ................................ .........................  65 
8.9 Health Economics  ................................ ................................ ................................ ...............  65 
9 Statistical Considerations ................................ ................................ ................................ ........  65 
9.1 Statistical Hypotheses  ................................ ................................ ................................ .........  65 
9.2 Analysis Populations  ................................ ................................ ................................ ..........  65 
9.3 Statistical Analyses  ................................ ................................ ................................ .............  66 
9.3.1  General Considerations  ................................ ................................ ................................ .. 66 
9.3.1.1  Protocol Deviations ................................ ................................ ................................ ..... 66 
9.3.1.2  Patient Disposition  ................................ ................................ ................................ ...... 66 
9.3.1.3  Demographic and Anthropometric Information and Baseline Characteristics  ...........  67 
9.3.2  Primary Endpoint(s) Analysis  ................................ ................................ .........................  67 
9.3.2.1  Prior and Concomitant Medication  ................................ ................................ .............  67 
9.3.2.2  Exposure  ................................ ................................ ................................ .....................  67 
9.3.2.3  Adverse Events  ................................ ................................ ................................ ...........  67 
9.3.2.4  Clinical Laboratory Tests ................................ ................................ ............................  68 
9.3.2.5  Vital Signs ................................ ................................ ................................ ...................  68 
9.3.2.6  Standard 12 -lead Electrocardiogram  ................................ ................................ ..........  68 
9.3.2.7  Telemetry  ................................ ................................ ................................ ....................  68 
9.3.2.8  Physical Examination  ................................ ................................ ................................ . 68 
9.3.3  Secondary Endpoint(s) Analysis  ................................ ................................ .....................  68 
9.3.3.1  Pharmacokinetics Analyses  ................................ ................................ ........................  68 
Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 8 of 98 12 Dec 2022 
 9.3.4  Other Analyses  ................................ ................................ ................................ ................  69 
9.3.4.1  Exploratory Analyses  ................................ ................................ ................................ .. 69 
9.4 Sample Size Determination  ................................ ................................ ................................  69 
10 Supporting Documentation and Operational Considerations  ................................ .................  70 
10.1  Appendix  1: Regulatory, Ethical, and Study Oversight Considerations  ............................  70 
10.1.1  Regulatory and Ethical Considerations  ................................ ................................ ..........  70 
10.1.2  Financial Disclosure  ................................ ................................ ................................ ....... 71 
10.1.3  Informed Consent Process  ................................ ................................ ..............................  71 
10.1.4  Data Protection  ................................ ................................ ................................ ...............  71 
10.1.5  Committees Structure  ................................ ................................ ................................ ..... 72 
10.1.6  Dissemination of Clinical Study Data  ................................ ................................ ............  72 
10.1.7  Data Quality Assurance  ................................ ................................ ................................ .. 72 
10.1.8  Source Documents  ................................ ................................ ................................ ..........  74 
10.1.9  Study and Site Start and Closure  ................................ ................................ ....................  74 
10.1.10  Publication Policy  ................................ ................................ ................................ ...........  75 
10.1.11  Protocol Approval and Amendment  ................................ ................................ ...............  76 
10.1.11.1  Access to Source Data  ................................ ................................ ................................  76 
10.2  Appendix  2: Clinical Laboratory Tests  ................................ ................................ ...............  77 
10.3  Appendix  3: Adverse Events and Serious Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  ................................ .............................  79 
10.3.1  Definition of Adverse Event  ................................ ................................ ...........................  79 
10.3.2  Definition of Serious Adverse Event  ................................ ................................ ..............  80 
10.3.3  Recording and Follow -up of Adverse Event, Ser ious Adverse Event, and Adverse Event 
of Special Interest  ................................ ................................ ................................ ...........  81 
10.3.4  Reporting of Serious Adverse Event and Adverse Event of Speci al Interest  .................  83 
10.4  Appendix  4: Contraceptive and Barrier Guidance  ................................ .............................  85 
10.4.1  Definitions  ................................ ................................ ................................ ......................  85 
10.4.2  Contraception Guidance  ................................ ................................ ................................ . 85 
10.4.2.1  Collection of Pregnancy Information  ................................ ................................ .........  88 
10.5  Appendix  5: Genetics  ................................ ................................ ................................ .........  89 
10.6  
 
 
 
 ................................ ................................ ................................ ............................  90 
10.7  Appendix  7: Abbreviations and Definitions  ................................ ................................ ....... 94 
11 References ................................ ................................ ................................ ...............................  98 

Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 9 of 98 12 Dec 2022 
  
List of Tables  
Table  1-1 Schedule of Activities  ................................ ................................ ...........................  18 
Table  2–1 Risk Assessment ................................ ................................ ................................ .... 25 
Table  3–1 Objectives and Endpoints  ................................ ................................ .....................  30 
Table  6–1 Study Intervention(s) Administered  ................................ ................................ ...... 43 
Table  6–2 Study Cohorts ................................ ................................ ................................ ........  44 
Table  6–3 Measures to Minimize Bias  ................................ ................................ ..................  45 
Table  9–1 Patient Analysis Population  ................................ ................................ ..................  66 
Table  10–1 Protocol -required Safety Laboratory Tests  ................................ ...........................  77 
 
List of Figures  
Figure  1–1 Study Design  ................................ ................................ ................................ .........  17 
Figure  4–1 Study Flow Chart – Multiple Ascending Dose Design  ................................ .........  35 
 
Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 10 of 98 12 Dec 2022 
 1 Protocol Summary  
1.1 Synopsis  
Protocol Title:  A Phase 1, Randomized, Placebo -controlled, Double -blind, Multiple Ascending 
Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral Doses of TCK -276 
in Patients with Rheumatoid Arthritis  
Brief Title: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral Doses of 
TCK -276 in Patients with Rheumatoid Arthritis  
Sponsor Protocol  No.: TCK-276-102 
Study Phase:  1 
Sponsor:  Teijin America, Inc.  
Rationale : 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial inflammation and 
hyperplasia. Activated lymphocytes and macrophages produce various proinflammatory 
mediators which recruit synovial fibroblasts to the joint and activate them. Pr oliferation of 
activated synovial fibroblasts further increases production of proinflammatory mediators and 
tissue -degrading proteinase such as matrix metalloproteinase -3 (MMP -3), resulting in 
irreversible destruction of bone and cartilage. The current tre atment approaches include 
conventional, biological, and targeted synthetic disease modifying antirheumatic drugs 
(DMARDs ). However, a high proportion of patients only show a partial response or fail to 
respond to DMARDs currently on the market even used in  combination. Therefore, there is a 
persistent unmet medical need for novel orally active agents with greater efficacy and equivalent 
or better safety with an alternative mechanism of action.  
Teijin America, Inc.,  (hereafter referred to as Sponsor)  has dev eloped TCK -276 (Laboratory 
code number: TEI -T01276) as a novel synthetic DMARD with an alternative mechanism of 
action for the treatment of RA. The Sponsor has conducted the Phase 1 single ascending dose 
(SAD) study using an orally administered capsule containing 5  mg or 50  mg of TCK -276. The 
Sponsor thereafter plans to develop TCK -276 using  an orally administered tablet containing 
10 mg or 25 mg of TCK -276. 
TCK -276 is a highly potent, orally active, and selective cyclin dependent kinase 4/6 (CDK4/6) 
inhibitor. Historically, CDK4/6 has been extensively explored as a target for anti -cancer 
therapeutics , however there is also mechanistic evidence to suggest that  CDK4/6 contributes to 
Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 11 of 98 12 Dec 2022 
 the pathogenesis of RA. Cyclin dependent kinase 4/6 is a key regulator at G1/S phase checkpoint 
in the cell cycle. Cyclin dependent kinase 4/6 forms a complex with D -type cyclins (CycD) and 
phosphorylates retinoblastoma protein (Rb),  leading to depression of transcription factor E2F to 
accelerate S  phase transition. Thus, inhibition of CDK4/6 leads to G1 arrest, and cell cycle 
progression is attenuated in synovial fibroblasts. In addition to the regulation of cell cycle, 
CDK4/6 has be en reported to mediate the production of MMP -3 and monocyte chemoattractant 
protein 1 via Rb -independent and dependent pathways. Cyclin dependent kinase 4/6 likely 
contributes to the pathogenesis of RA by mediating the proliferation of synovial fibroblasts  and 
the production of MMP -3. The inhibition of CDK4/6 may serve a useful therapeutic strategy for 
RA patients, particularly those with an inadequate response to existing DMARDs.  
Objectives and Endpoints :  
Objectives  Endpoints  
Primary  
• To evaluate the safety and tolerability 
of multiple  oral doses of TCK 276 in 
patients with rheumatoid arthritis (RA)  • Safety and tolerability endpoints:  
The following safety and to lerability variables 
will be recorded at regular intervals during the 
study:  
o Vital signs measurements: supine blood 
pressure, pulse, body temperature , and 
respiratory rate  
o Cardiac safety for  arrythmias, 
abnormalities including PR interval, 
QRS interval, RR interval, QT interval, 
and QT interval corrected for heart rate 
(QTc) (Fride ricia’s correction [QTcF]) 
as assessed by 12-lead 
electrocardiogram (ECG) and cardiac 
telemetry  
o Incidence of laboratory abnormalities: 
hematology, clinical chemistry, 
coagulation, and urinalysis  
o Incidence and severity of a dverse event 
(AE) and adverse even t of special 
interest (AESI) (i.e., gastrointestinal 
toxicity and pulmonary symptoms 
indicative of interstitial lung disease) 
assessments  
o Physical examinations  
Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 12 of 98 12 Dec 2022 
 Objectives  Endpoints  
Secondary  
• To evaluate pharmacokinetic ( PK) of 
TCK -276 and its metabolite 
(TEI -W00595) in patients with RA 
after multiple ascending dose (MAD) 
administration  • PK endpoints  
The following PK parameters for TCK -276 and 
TEI-W00595 will be determined, if calculable:  
o Cmax: Maximum plasma concentration 
determined directly from the 
concentration -time pr ofile (Days  1 and 
7) 
o tmax: Time of maximum plasma 
concentration determined directly from 
the concentration -time profile (Days  1 
and 7)  
o AUC tau: Area under the plasma 
concentration -time curve over a dosing 
interval, tau  = 24 hours (Days  1 and 7)  
o AUC 0-t: Area under the plasma 
concentration -time curve up to last 
measurable concentration (Days  1 and 
7) 
o AUC 0-inf: Area under the plasma 
concentration -time curve from pre -dose 
(time 0) extrapolated to infinite time 
(Days  1 and  7) 
o MRT last: Mean residence time up t o last 
measurable concentration (Day  1 only)  
o MRT 0-inf: Mean residence time 
extrapolated to infinity (Days  1 and  7) 
o t½: Terminal elimination half -life 
(Days  1 and  7) 
o CL/F: Apparent total body clearance 
(Days  1 and 7), determined for parent 
only 
o Vz/F: Appare nt volume of distribution 
based on terminal phase (Days  1 and  7), 
determined for parent only  
o Metabolic ratio (MR) for C max: Molar 
metabolic ratio of C max calculated as 
(Cmax [metabolite]  × molecular weight 
of parent)/(C max [parent]  × molecular 
weight of metabolite)  (Days  1 and 7)  
Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 13 of 98 12 Dec 2022 
 Objectives  Endpoints  
o MR for area under the plasma 
concentration -time curve (AUC): Molar 
metabolic ratio of AUC calculated as 
(AUC [metabolite]  × molecular weight 
of parent)/(AUC [parent]  × molecular 
weight of metabolite)  (Days  1 and 7)  
o Ctrough: Concentration  in a dosing period 
defined as the pre -dose concentration of 
the day  
o Racc (Cmax): Accumulation ratio based 
on Cmax: Calculated as C max on 
Day 7/C max on Day  1 
o Racc (AUC tau): Accumulation ratio based 
on AUC tau: Calculated as AUC tau on 
Day 7/AUC tau on Day  1 
The following urinary PK parameters for 
TCK -276 will be determined in this study:  
o Ae: Amount of study drug excreted 
unchanged in the urine (Days  1 and 7)  
o Fe: Percentage of study drug excreted 
unchanged in the urine (Days  1 and 7)  
o CL r: Renal cle arance (Days  1 and 7)  
Other PK parameters will be determined if 
needed.  
Exploratory  
• To evaluate the effect of TCK -276 on 
disease activity and  biomarkers in 
patients with RA  • Exploratory  endpoints  
The following exploratory disease activity 
parameters for RA will be assessed:  
o American College of Rheumatology 
(ACR) 20/50/70  response criteria  
o Disease activity score  28 (DAS28)  
o Clinical disease activity index  (CDAI)  
o Simplified disease activity index 
(SDAI)  
The following exploratory  biomarkers will be 
assessed:  
o Matrix metalloproteinase -3 (MMP -3) 
o Granulocyte macrophage 
colony -stimulating factor (GM -CSF)  
Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 14 of 98 12 Dec 2022 
 Objectives  Endpoints  
o C-X-C motif chemokine ligand  10 
(CXCL10)  
o C-C motif chemokine ligand 2 (CCL2)  
o Cartilage oligomeric matrix protein 
(COMP)  
o Tumor necrosis factor ( TNF )-alpha  
o TNF -R1 
o Interleukin -6 (IL-6) 
Overall Design : 
This is a Phase  1, multi -center, double -blind, randomized, placebo -controlled, multiple ascending 
dose ( MAD ) study to evaluate the safety, tolerability, and pharmacokinetic s (PK) of orally 
administered TCK -276 in both males and females with RA. Blood samples for possible future 
pharmacogenetic , possible future metabolite assessments , and possible future pharmaco dynamic 
(PD) assessments will be collected.  
A total of thirty -two (32) patients with RA will be enrolled in this clinical study. This MAD study 
will consist of 4 cohorts of 8  patients  (6 active treatment and 2  matching placebo , or a 3:1 ratio), 
each receiv ing an oral dose of TCK -276 or matching placebo for 7  days ( once daily  [QD] under 
fed condition). The first cohort will be divided into 2  subgroups to implement the sentinel dosing 
approach. Within the cohort, the first subgroup will consist of 2  sentinel patients; one patient will 
receive TCK -276, and one patient will receive matching placebo. The second subgroup will 
consist of 6  patients (5  active treatment, 1  matching placebo). Individual patients in the second 
subgroup will be dosed at least 72  hours after the first dose of  the second sentinel  patient  of the 
first subgroup following a decision by the Investigators based on all available safety data from 
the sentinel patients up to 48  hours post -dose. Subsequent cohorts (cohort 2 -4) will not include 
the sentinel dosing approach . 
Patients will be  admitted to the site from the morning of Day  -1 and sequestered for the duration 
of the treatment (dosing) period . Each patient will receive QD oral doses of either TCK -276 or 
matching placebo administered as tablets  under fed condition in the morning of Day 1 to Day  7. 
The patients will be discharged on Day  10. The planned dose levels to be tested are 10 mg 
(Cohort  1), 25 mg (Cohort  2), 75 mg (Cohort  3), and 150  mg (Cohort  4) of TCK -276. Based on 
the results from the SAD study (5  mg to 185  mg dosing) and the projected clinical effective dose 
(i.e., 75 mg), 10  mg is selected as the starting dose level in the MAD study. The dose in 
Cohorts  2, 3, and 4  may be adjusted based on the safety and PK results from the previous 
cohorts, if necessary. The overall expo sure to TCK -276 (in terms of geometric mean area under 
Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 15 of 98 12 Dec 2022 
 the plasma concentration -time curve over a dosing interval [AUC tau, tau = 24 hours]) on Day  7 
would not be expected to exceed  
. 
Dose escalation will only be allowed after blinded assessment of all safety, tolerability, and PK 
data up to Day  10 from each previous cohort evaluated by Investigators, Medical Monitor, and 
Sponsor representatives during the Safety  Review Committee  (SRC ) meeting . 
Brief Summary:  
The purpose of this study is to evaluate the safety, tolerability, and PK of multiple orally 
administered TCK -276 in both males and  females with RA.  
Study details include:  
• Study d uration : approximately 42 days  
• Treatment duration : Up to 11 days (Day  -1 to Day 10)  
• Visit frequency : Screening Visit, Days  -1 to 10  Visits; Follow -up/end of treatment (EOT) 
Visit. Following discontinuation of TCK -276, patients will be followed unless they withdraw 
their informed consent for study participation.  
Number of Patients : 
A total of 32 patients  with RA are planned for enrollment and randomized into 4 cohorts with 
8 patients per cohort. Within each cohort, 6  patients will be randomized to TCK -276 and 
2 patients will be randomized to matching placebo.  
Note : “Enrolled ” means a participant’s , or their legall y acceptable representative’s, agreement to 
participate in a clinical study following completion of the informed consent process  and 
Screening . Potential participants who are screened for the purpose of determining eligibility for 
the study, but do not par ticipate in the study, are not considered enrolled, unless otherwise 
specified by the protocol . A participant will be considered enrolled if the informed consent is not 
withdrawn prior to participating in any study activity after Screening.  
Intervention  Groups  and Duration : 
This MAD study will consist of 4 cohorts of 8  patients  (6 active treatment and 2  matching 
placebo , or a 3:1 ratio), each receiving an oral dose of TCK -276 or matching placebo for 7  days 
(QD under fed condition). The first cohort will be divided into 2  subgroups to implement the 
sentinel dosing approach. Within the cohort, the first subgroup will consist of 2  sentinel patients; 

Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 16 of 98 12 Dec 2022 
 one patient will receive TCK -276, and one p atient will receive matching placebo. The second 
subgroup will consist of 6  patients (5  active treatment, 1  matching placebo). Individual patients 
in the second subgroup will be dosed at least 72  hours after the first dose of the second sentinel 
patient of  the first subgroup following a decision by the Investigators based on all available 
safety data from the sentinel patients up to 48  hours post -dose.  Subsequent cohorts (cohort 2 -4) 
will not include the sentinel dosing approach . 
Patients will be admitted t o the site from the morning of Day  -1 and sequestered for the duration 
of the treatment (dosing) period. Each patient will receive QD oral doses of either TCK -276 or 
matching placebo administered as tablets  under fed condition in the morning of Day  1 to Da y 7. 
The patients will be discharged on Day  10. The planned dose levels to be tested are 10 mg 
(Cohort  1), 25 mg (Cohort  2), 75 mg (Cohort  3), and 150  mg (Cohort  4) of TCK -276. Based on 
the results from the SAD study (5  mg to 185  mg dos es) and the projected clinical effective dose 
(i.e., 75  mg), 10  mg is selected as the starting dose level in the MAD study.  The dose in 
Cohorts  2, 3, and 4 may be adjusted based on the safety and PK results from the previous 
cohorts, if necessary.  
Dose Group  Treatment  Assignment  
1 10 mg TCK -276 (N  = 6) Placebo (N  = 2) 
2 25 mg TCK -276 (N  = 6) Placebo (N  = 2) 
3 75 mg TC K-276 (N  = 6) Placebo (N  = 2) 
4 150 mg TCK -276 (N  = 6) Placebo (N  = 2) 
Data Monitoring /Other Committee:  
A SRC  will be appointed for this study. The SRC meeting will take place to review safety  and 
PK data during each dose level . The SRC will evaluate  the safety and tolerability data up to 
Follow -up/EOT  Visit and available PK data up to Day  10 to determine the next dose  for the 
subsequent cohort . 
Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final ; Version 3.0 17 of 98 12 Dec 2022 
 1.2 Schema  
Figure  1–1 Study Design  
 
N = number of patients; PK = pharmacokinetics ; SRC  = Safety Review Committee.  
 

Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final; Version 3.0 18 of 98 12 Dec 2022 1.3 Schedule of Activities  
Table  1-1 Schedule of Activities  
Evaluation  Screening 
visit Treatment period  Follow -up/ 
End of 
treatment  Early termination 
procedures  
Days 
-28 to -2 -1 1 2-7 8, 9 10 14  
Informed consent  X        
Admission   X       
In-house stay   X X X X X   
Ambulatory visits  X      X X 
Discharge       X   
Inclusion/exclusion criteria  X X X      
Medical history  X X       
Disease activity data (ACR20/50/70, 
DAS28, CDAI, SDAI)    X1 X2     
Blood sampling  for ESR, assessed as part 
of disease activity data    X1 X2     
Demographics  X        
Weight and height (height only at 
Screening)  X X    X   
Viral serology (HBsAG, anti -HBc, 
anti-HCV, anti -HIV)  X        
Drug, alcohol, and cotinine screen  X X       
SARS -CoV -2 real time RT -PCR  X X       
IGRA -TB test (Quantiferon)  X        
Chest X -ray X        
Randomization    X      
Study drug administration    X X     
Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final; Version 3.0 19 of 98 12 Dec 2022 Evaluation  Screening 
visit Treatment period  Follow -up/ 
End of 
treatment  Early termination 
procedures  
Days 
-28 to -2 -1 1 2-7 8, 9 10 14  
Urine pregnancy test (females)  X X     X X 
FSH (post -menopausal females)  X        
Physical examination3 X X    X X X 
Clinical laboratory tests (clinical chemistry, 
hematology, coagulation, and urinalysis)  X X X1 X4 X X X X 
Vital signs  X X X5 X X X X X 
12-lead ECG6 X6 X7 X8 X8 X X X X 
Telemetry    X9 X9     
PK blood sampling10   X X X X   
PK urine collection11   X X X X   
Biomarker blood sampling    X1 X2     
Blood sampling for possible future 
pharmacogenetic assessments   X12       
Blood sampling for possible future 
metabolite assessments10   X X X X   
Blood sampling for possible future PD 
assessments    X1 X2     
Prior/concomitant medications  X X X X X X X X 
AE monitoring13 X X X X X X X X 
ACR  = American College of Rheumatology; AE = adverse event; CDAI  = clinical disease activity index; DAS 28 = disease activity score  28; 
ECG  = electrocardiogram; ESR = erythroc yte sedimentation rat e; FSH = follicle stimulating hormone; HBc  = hepatitis B core; HBsAG  = hepatitis B surface 
antigen; HCV  = hepatitis C virus; HIV  = human immunodeficiency virus; ICF  = informed consent form; IGRA -TB = interferon gamma release assay for 
tuberculosis; PD = pharmacodynamic; PK = pharmacokinetics; RT -PCR  = reverse transcription polymerase chain reaction; SARS -CoV-2 = severe acute 
respiratory syndrome coronavirus 2 ; SDAI  = simplified disease activity index . 
Teijin America, Inc.  Clinical Study Protocol  
TCK -276-102  CONFIDENTIAL  
Final; Version 3.0 20 of 98 12 Dec 2022 1. Disease activity data  (ACR20/50/70, DAS28, CDAI, SDAI , and  blood sampling for ESR ), blood for clinical laboratory tests, blood for biomarker 
assessments, and blood for possible future PD assessments will be collected pri or to dosing on Day  1. Blood sampling for ESR will be collected and 
assessed  at local laboratory . 
2. Disease activity data  (ACR20/50/70, DAS28, CDAI, SDAI, and blood sampling for ESR) , blood for biomarker assessments, and blood for possible future 
PD assessments will be collected prior to dosing on Day  7 only. Blood sampling for ESR will be collected and assessed  at local laboratory . 
3. A full physical examination will be performed at the  Screening Visit, Day  14, and Early termination visit; a brief physical will be performed on Days  -1 and 
10. 
4. Blood for clinical laboratory tests will be withdrawn once on Days 4 and 7.  
5. Vital signs will be collected at pre -dose and 1, 2, 4, 8, and 12 hours  after dosing on Day  1. 
6. 12-lead ECG will be conducted before blood sampling.  
7. 12-lead ECG will be repeated once for eligibility confirmation at Screening and Day -1. 
8. 12-lead ECG will be recorded at baseline and at 1, 2, 4, and 8 hours after dosing on Days  1 and 7.  
9. Starting 2  hours prior to dosing and until 12  hours after dosing on Days  1 and 7.  
10. Blood for PK sample analysis to determine parent and its metabolite concentrations and for possible future metabolite assessm ents will be sampled at 
pre-dose and 0.2 5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24  hours (pre -dose of Day  2) after dosing on Day  1, pre -dose on Days 3, 4, 5, 6 , and on 7 at pre -dose 
and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, and 72  hours after dosing on Day  7 (the sampling time poi nts may be adjusted based on the PK results 
obtained from the previous parts or cohorts). The last dose will be administered on Day  7. 
11. Urine for PK sample analysis will be collected at 0 (pre -dose) to 6, 6 to 12, and 12 to 24 hours after dosing on Day 1, a nd from 0 (pre -dose) to 6, 6 to 12, 12 
to 24, 24 to 48, and 48 to 72 hours after dosing on Day  7. Urine collection intervals may be adjusted based on the PK results obtained from the previous 
parts or cohorts, e.g., if plasma PK sampling times are adjusted , the urine sampling times will be updated.  
12. Sample will be obtained only from patient s that consent to pharmacogenomics sampling.  
13. Any AEs occurring after the patient signs the ICF will be collected and monitored throughout the study via safety assessments, observation, and  patient 
reporting.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 21 of 98 12 Dec 2022 2 Introduction  
TCK -276 is a highly potent, orally active, and selective cyclin dependent kinase 4/6 (CDK4/6) 
inhibitor.  The Sponsor is planning to develop TCK -276 as a novel synthetic disease modifying 
antirheumatic drug (DMARD) with an alternative mechanism of action for the treatment of 
rheumatoi d arthritis (RA).  
The term “study intervention” throughout the protocol, refers to  TCK -276. 
2.1 Study Rationale  
Rheumatoid arthritis  is an autoimmune disease characterized by synovial inflammation and 
hyperplasia. Activated lymphocytes and macrophages produce various proinflammatory 
mediators which recruit synovial fibroblasts to the joint and activate them. Proliferation of 
activated synovial fibroblasts further increases production of proinflammatory mediators and 
tissue -degrading proteinase such as matrix metalloproteinase -3 (MMP -3), resulting in 
irreversible destruction of bone and cartilage1,2. The current treatment approaches include 
conventional, biological, and targeted synthetic DMARDs. However, a high proportion of 
patients only show a partial response or fail to respond to DMARDs  currently on the market even 
used in combination . Therefore,  there is a persistent unmet medical need for novel orally active 
agents with greater efficacy and equivalent or better safety with an alternative mechanism of 
action.  
Teijin America, Inc.,  (hereafter referred to as Sponsor)  has developed TCK -276 (Laborato ry 
code number: TEI -T01276) as a novel synthetic DMARD with an alternative mechanism of 
action for the treatment of RA. The Sponsor has conducted the Phase 1 single ascending dose 
(SAD) study using an orally administered capsule containing 5  mg or 50  mg of  TCK -276. The 
Sponsor thereafter plans to develop TCK -276 using  an orally administered tablet containing 
10 mg or 25 mg of TCK -276. 
TCK -276 is a highly potent, orally active, and selective CDK4/6 inhibitor. Historically, CDK4/6 
has been extensively explored as a target for anti -cancer therapeutics , however there is also 
mechanistic evidence to suggest that CDK4/6 contributes to the pat hogenesis of RA3. Cyclin 
dependent kinase 4/6 is a key regulator at G1/S phase checkpoint in the cell cycle. Cyclin 
dependent kinase 4/6 forms a com plex with D -type cyclins (CycD) and phosphorylates 
retinoblastoma protein (Rb), leading to depression of transcription factor E2F to accelerate 
S phase transition3,4. Thus, inhibition of CDK4/6 leads to G1 arrest, and cell cycle progression is 
attenuated in synovial fibroblasts5. In addition to the regulation of cell cycle, CDK4/6 has been 
reported to mediate the production of MMP -3 and monocyte chemoattractant protein 1 via 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 22 of 98 12 Dec 2022 Rb-independent and dependent pathways6. Cyclin dependent kinase 4/6 likely contributes to the 
pathogenesis of RA by mediating the proliferation of synovial fibroblasts and the production of 
MMP -3. The inhibition of CDK4/6 may serve a useful therapeutic strategy for RA patients, 
particularly those with an inadequate response to existing DMARDs.  
This multiple ascending dose (MAD) study will evaluate the safety, tolerability, and 
pharmacokinetic ( PK) of orally administered TCK -276 in both male and female patients with 
RA. 
The study is being conducted to establish a dose range that is well tolerated by the majority of 
study patients with RA and to provide exploratory data on the potential for the treatment of RA. 
The results of the clinical study will inform the design and dose selection of subsequent studies.  
2.2 Background  
2.2.1 Summary of Findings from Non -clinical Studies with Potential Clinical 
Relevance  
Pharmacodynamic (PD) studies demonstrated that TCK -276 inhibits CDK4/6 and has mi nimal 
potential for off -target kinase activity (Sections 5.1.1.2 and 5.1.2 of the Investigator’s Brochure 
[IB]7). 
Results of in vitro  pharmacology study using rheumatoid arthritis synovial fibroblasts (RASF) 
indicated that TCK -276 inhibited proliferation and MMP -3 production of RASF 
(Section  5.1.1.2.5 and 5.1.1.2.6 of the IB).  
Results of in vivo  pharmacology studies using rat and mouse arthritis models, indicated that 
TCK -276 at ≥  15 mg/kg of tested doses was effective in the treatment of arthritis with no effect 
on bone marrow nucleated cells in rat arthritis model and TCK -276 at doses of ≥  6.25 mg/kg was 
effective in the treatment of a rthritis and bone destruction in mouse arthritis model 
(Section s 5.1.1.3.1 and 5.1.1.3.2 of the IB7). 
Safety pharmacology studies were performed in vitro  and in vivo  (cardiovascular, central 
nervous, and respiratory systems) in rats and monkeys. No untoward effects were observed in 
these stu dies.  

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 23 of 98 12 Dec 2022 

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 24 of 98 12 Dec 2022 TCK -276 was not genotoxic based on the absence of mutagenic potential in bacterial reverse 
mutation, the absence of potential for inducing chromosomal aberration in human lymphocytes 
in vitro  and in rat bone marrow in vivo  (Section 5.3.3.2 of the IB7). 
Embryo -fetal development studies have revealed evidence for teratogenicity in rats and rabbits 
and post -implantation loss (embryotoxicity) in rabbits (Section 5.3.5.3 of the IB7). In the male 
fertility study, there were no effects on the reproductive function of males or on early embryonic 
development when treated males were mated with untr eated females (Section 5.3.5.1 of the IB7).  
Based on the non -good laboratory practice preliminary phototoxicity study  (non-good laboratory 
practice grade) , TCK -276 is considered to have no phototoxic potential (Section 5.3. 7.1 of the  
IB7). 
In summary, the preclinical program supports the clinical development of TCK -276, as a once 
daily, self -administered, oral product for RA treatment. Collectively, the available data indicate 
that TCK -276 can be useful in the treatment of RA.  
2.2.2 Summary of Findings from Previous Clinical Studies  
The first -in-human (FIH) Phase  1 SAD study (Study TCK -276-101) evaluating TCK -276 has 
completed ; 48 subjects have been orally administered capsules ranging from 5 to 
185 mg (geometric mean of AUC 0-inf: 39.7 to 2,260 ng·h/mL) once daily (QD). Clinical data 
from the SAD study of TCK -276 showed no drug -related safety signals (i. e., serious adverse 
events [SAE s], adverse events [AEs] leading to discontinuation). The plasma exposure levels for 
TCK -276 linearly increased following escalating TCK -276 administration with the proportion of 
metabolite (TEI -W00595) to parent remaining si milar across dose levels. It was noted  that no 
clinically meaningful differences in PK parameters were observed between fed or fasting  states 
for either TCK -276 or its metabolite.  
A detailed description  of the chemistry, pharmacology, efficacy, and safety of TCK -276 is 
provided in the IB. 

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 25 of 98 12 Dec 2022 2.3 Benefit/Risk Assessment  
The risks of TCK -276 known to date are outlined in Section  2.3.1  and the benefits are outlined in 
Section  2.3.2 . More detailed information about the known and expected benefits and risks and 
reasonably expected  AEs of TCK -276 can be found in the IB. 
2.3.1 Risk Assessment  
Table  2–1 Risk Assessment  

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 26 of 98 12 Dec 2022 

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 28 of 98 12 Dec 2022 Measures to mitigate the additional risks caused by COVID -19 are:  
• This study is going to start enrolling only when the Sponsor and contract research 
organization (CRO) in collaborati on deem it is safe to start the study. In addition, the study 
will not start until the local containment  measures or other safety restrictions linked to the 
COVID -19 pandemic allow.  
• Current national  laws and local recommendations for prevention of pandemic  will be strictly 
adhered to.  
• Patient s will be closely monitored for any signs and symptoms of COVID -19, including 
fever, dry cough, dyspnea, sore throat, fatigue, and changes of taste and smell throughout the 
study. Once clinical signs of infection are re ported by patients, the Investigator needs to 
determine whether samples can be collected, and safety data can be recorded on -site. If not, 
information on AEs and concomitant medications will be obtained via phone calls.  
• Confirmation of COVID -19 infection b y available approved laboratory standard testing 
should be conducted at Investigator’s discretion. This would include serology testing at 
Screening and virus testing prior to any Admission.  
• The probability of virus transmission will be controlled as much a s possible by:  
o Advice for patients to adhere to local requirements for reduction of the public exposure 
while ambulatory.  
o Asking the potential patients to self -isolate for at least 5 days prior to admission.  
o Contacting patients by phone 1 day prior to every visit for assessing COVID -19 
symptoms and signs , and patients will be asked not to attend the site in case of 
suspected reports. In addition, patients will be asked  about any contact with a person 
who has t ested positive for SARS -CoV -2. If applicable, patients will be referred to the 
local health care system for further follow -up and treatment.  
o Physical distancing  and person -to-person contact restrictions will be applied during site 
visits.  
o Where physical distancing  is not possible, face shields will be used by study patients 
(surgical face mask, and gloves) and staff (for example but not limited to masks, gloves, 
protectors, and medical suits) if deemed appropriate by the Investigators and site staff 
and gui ded by local requirements.  
o Logistical improvements of the site and structural measures of the study site building 
will be implemented to further improve physical distancing.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 29 of 98 12 Dec 2022 • Patients  will follow  the site policy to mitigate the additional risks caused by CO VID-19. All 
medical measures, risk/benefit, and restrictions associated with COVID -19 screening will be 
explained by the informed consent for COVID -19 screening,  and written consent must be 
obtained before participating in the clinical study . Patients will be allowed to receive 
COVID -19 vaccines or boosters during the study period if necessary.  
2.3.2 Benefit Assessment  
TCK -276 is a highly potent, orally active, and selective CDK4/6 inhibitor as a novel synthetic 
DMARD with an alternative mechanism of action for the treatment of RA.  
The protocol has been designed to minimize the risk to research patient s. Patients will be 
monitore d to detect AEs during the study and followed appropriately to ensure resolution of 
AEs. Sentinel dosing will be employed within the first  cohort, and available safety /tolerability  
and PK data will be assessed after each dose level to determine if it is sa fe to escalate to the next 
planned higher dose.  
Based on CDK4/6 inhibition mechanism of action, the adverse event of special interest (AESI) 
will be monitored as described in Section  2.3.1 .  
Given the safety and tolerability profile of TCK -276 in preclinical studies  and the SAD study , 
also in view of the short treatment duration  of 7 days, the overall risk to the patients in this study 
is deemed to be low  and the patients cannot derive benefit from short term treatment . The study 
results will help to further develop TCK -276 as potential treatment for RA patients in future and 
will guide researchers to plan and design future studies. Therefore, the Sp onsor considers that it 
is medically and ethically acceptable to perform the proposed study.  
2.3.3 Overall Benefit /Risk Conclusion  
Taking  into account the measures taken to minimize risk to patient s participating in this study, 
the potential risks identified in association with TCK -276 are justified by the anticipated benefits 
that may be afforded to patients with RA . 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 30 of 98 12 Dec 2022 3 Objectives  and Endpoints  
Study objectives and endpoints are summarized in  Table  3–1. 
Table  3–1 Objectives  and Endpoints  
Objectives  Endpoints  
Primary  
• To evaluate the safety and tolerability 
of multiple oral doses of TCK 276 in 
patients with rheumatoid arthritis (RA)  • Safety and tolerability endpoints:  
The following safety and tolerability variables 
will be recorded at regular intervals during the 
study:  
o Vital signs measurements: supine blood 
pressure, pulse, body temperature, and 
respiratory rate  
o Cardiac safety for  arrythmias, 
abnormalities including PR interval, 
QRS interval, RR interval, QT interval, 
and QT interval corrected for heart rate 
(QTc) (Fride ricia’s correction [QTcF]) 
as assessed by 12-lead 
electrocardiogram (ECG) and cardiac 
telemetry  
o Incidence of laboratory abnormalities: 
hematology, clinical chemistry, 
coagulation, and urinalysis  
o Incidence and severity of adverse event 
(AE) and adverse even t of special 
interest (AESI) (i.e., gastrointestinal 
toxicity and pulmonary symptoms 
indicative of interstitial lung disease) 
assessments  
o Physical examinations  
Secondary  
• To evaluate pharmacokinetic (PK) of 
TCK -276 and its metabolite 
(TEI -W00595) in patients with RA 
after multiple ascending dose (MAD) 
administration  • PK endpoints  
The following PK parameters for TCK -276 and 
TEI-W00595 will be determined, if calculable:  
o Cmax: Maximum plasma concentration 
determined directly from the 
concentration -time profile (Days  1 and 
7) 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 31 of 98 12 Dec 2022 Objectives  Endpoints  
o tmax: Time of maximum plasma 
concentration determined directly from 
the concentration -time profile (Days  1 
and 7)  
o AUC tau: Area under the plasma 
concentration -time curve over a dosing 
interval, tau  = 24 hours (Days  1 and 7)  
o AUC 0-t: Area under the plasma 
concentration -time curve up to last 
measurable concentration (Days  1 and 
7) 
o AUC 0-inf: Area under the plasma 
concentration -time curve from pre -dose 
(time 0) extrapolated to infinite time 
(Days  1 and  7) 
o MRT last: Mean residence time up to last 
measurable concentration (Day  1 only)  
o MRT 0-inf: Mean residence time 
extrapolated to infinity (Days  1 and  7) 
o t½: Terminal elimination half -life 
(Days  1 and  7) 
o CL/F: Apparent total body clearance 
(Days  1 and 7), determined for parent 
only 
o Vz/F: Apparent volume of distribution 
based on terminal phase (Days  1 and  7), 
determined for parent only  
o Metabolic ratio (MR) for C max: Molar 
metabolic ratio of C max calculated as 
(Cmax [metabolite]  × molecular weight 
of parent)/(C max [parent]  × molecular 
weight of metabolite) (Days  1 and 7)  
o MR for area under the plasma 
concentration -time curve (AUC): Molar 
metabolic ratio of AUC calculated as 
(AUC [metabolite]  × molecular weight 
of parent)/(AUC [parent]  × molecular 
weight of metabolite)  (Days  1 and 7)  
o Ctrough: Concentration in a dosing period 
defined as the pre -dose concentration of 
the day  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 32 of 98 12 Dec 2022 Objectives  Endpoints  
o Racc (Cmax): Accumulation ratio based 
on C max: Calculated as C max on 
Day 7/C max on Day  1 
o Racc (AUC tau): Accumulation ratio based 
on AUC tau: Calculated as AUC tau on 
Day 7/AUC tau on Day  1 
The following urinary PK parameters for 
TCK -276 will be determined in this study:  
o Ae: Amount of study drug excreted 
unchanged in the urine (Days  1 and 7)  
o Fe: Percentage of study drug excreted 
unchanged in the urine (Days  1 and 7) 
o CL r: Renal clearance (Days  1 and 7)  
Other PK parameters will be determined if 
needed.  
Exploratory  
• To evaluate the effect of TCK -276 on 
disease activity and biomarkers in 
patients with RA  • Exploratory endpoints  
The following exploratory disease activity 
parameters for RA will be assessed:  
o American College of Rheumatology 
(ACR) 20/50/70 response criteria  
o Disease activity score  28 (DAS28)  
o Clinical disease activity index  (CDAI)  
o Simplified disease activity index 
(SDAI)  
The following exploratory bioma rkers will be 
assessed:  
o Matrix metalloproteinase -3 (MMP -3) 
o Granulocyte macrophage 
colony -stimulating factor (GM -CSF)  
o C-X-C motif chemokine ligand  10 
(CXCL10)  
o C-C motif chemokine ligand 2 (CCL2)  
o Cartilage oligomeric matrix protein 
(COMP)  
o Tumor necrosis fact or (TNF) -alpha  
o TNF -R1 
o Interleukin -6 (IL -6) 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 33 of 98 12 Dec 2022 4 Study Design  
4.1 Overall  Design  
This is a Phase  1, multi -center, double -blind, randomized, placebo -controlled, MAD study to 
evaluate the safety, tolerability, and PK of orally administered TCK -276 in both males and 
females with RA. Blood samples for possible future pharmacogenetic, possible future metabolite 
assessments, and possible future pharmacodynamic (PD) assessments will be collected.  
A total of thirty -two (32) patients with RA will be en rolled in this clinical study. This MAD study 
will consist of 4 cohorts of 8  patients  (6 active treatment and 2  matching placebo , or a 3:1 ratio), 
each receiving an oral dose of TCK -276 or matching placebo for 7  days (QD under fed 
condition)  as shown in Figure  1–1. The first  cohort will be divided into 2  subgroups to 
implement the sentinel dosing approach. Within the cohort, the first subgroup will consist of 
2 sentinel patients; one patient will receive TCK -276, and one patient will receive matching 
placebo. The second subgro up will consist of 6  patients (5  active treatment, 1  matching placebo). 
Individual patients in the second subgroup will be dosed at least 72  hours after the first dose of 
the second patient of the first subgroup following a decision by the Investigators ba sed on all 
available safety data from the sentinel patients up to 48  hours post -dose.  Subsequent cohorts 
(cohort 2 -4) will not include the sentinel dosing approach . 
Patients will be admitted to the site from the morning of Day  -1 and sequestered for the du ration 
of the treatment (dosing) period . Each patient will receive QD oral doses of either TCK -276 or 
matching placebo administered as tablets  under fed condition in the morning of Day  1 to Day  7. 
The patients will be discharged on Day  10. The planned dose  levels to be tested are 10 mg 
(Cohort  1), 25 mg (Cohort  2), 75 mg (Cohort  3), and 150  mg (Cohort  4) of TCK -276. Based on 
the results from the SAD study (5  mg to 185  mg dosing) and the projected clinical effective dose 
(i.e., 75  mg), 10  mg is selected as t he starting dose level in the MAD study. The dose in 
Cohorts  2, 3, and 4 may be adjusted based on the safety and PK results from the previous 
cohorts, if necessary. The overall exposure to TCK -276 (in terms of geometric mean area under 
the plasma concentra tion-time curve over a dosing interval [AUC tau, tau = 24 hours]) on Day  7 
would not be expected to exceed  
. Further details are presented in  Figure  4–1. 
Dose escalation will only be allowed after blinded assessment of all safety, tolerability, and PK 
data up to Day 10 from each previous cohort  evaluated by Investigators, Medical Monitor, and 
Sponsor representatives during the Safety Review Committee  (SRC ) meeting .  

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 34 of 98 12 Dec 2022 All patients (including patients who terminate the study early) will return to the site 13 days after 
the first TCK -276 or TCK -276 matching placebo administration for follow -up procedures and 
for the end of treatment examination.  
Duration of patient partic ipation from the Screening Visit to the end of treatment examination 
will be approximately 42  days. This includes 27  days for the Screening period, 11  days for the 
in-house Treatment period (patients will be confined from the morning of Day  -1 until all sa fety 
assessments have been completed on Day  10), and 4  days after the end of the Treatment period, 
for the Follow -up/EOT  Visit.  
If the Investigator, the Sponsor, or the Medical Monitor becomes aware of conditions or events 
that suggest a possible hazard t o patients if the clinical study continues, the clinical study may be 
terminated after appropriate consultation between the involved parties. The clinical study may 
also be terminated at the Sponsor’s discretion in the absence of such a finding.  
 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 36 of 98 12 Dec 2022 4.2 Scientific Rationale for Study Design  
This study evaluates the safety, tolerability, and PK of ascending multiple doses of TCK -276 
administered as oral tablet (s). The design is standard and is considered appropriate to meet the 
objectives of this exploratory study.  
A double -blind, placebo -controll ed study is appropriate and standard for an ascending multiple 
dose study . This design will minimize bias and provide reference data (i.e., data from 
placebo -treated patients) which will aid in the interpretation of results. The SRC  will review 
available blinded safety, tolerability, and PK data after each cohort to confirm whether it is safe 
to proceed with the next planned dose, whether the dose escalation should be stopped, or if the 
dose should be lowered, repeated or titrated in the subseque nt cohort.  
The safety assessments for the study are accepted measures for ensuring safety of patients during 
a clinical study . The PK sampling schedule is considered appropriate given the information 
available. The justification for dose selection is discu ssed in Section  4.3. 
4.3 Justification for Dose  
In the SAD study, which included dose -levels up to 185  mg (capsule), TCK -276 was generally 
safe and well tolerated in healthy subjects with no reports of SAE s nor discontinuations due to 
AEs. The starting dose for the MAD study (10  mg, tablet) is sufficiently lower than the highest 
dose in the SAD study (185  mg, capsule), and the projected clinical effective dose (75  mg) that 
was calculated  from nonclinical pharmacological study using the rat adjuvant -induced arthritis  
model.  
Patients  with RA  will be enrolled in this MAD study. Given the data for recently approved RA 
drugs, an up to 2 -fold increased exposure in patients with RA compared to healthy subjects was 
taken into consideration as a conservative approach. Even if a 2-fold higher exposur e in patients  
with RA  would occur , the exposure of the 10 mg in the MAD study corresponds to 20  mg in 
healthy subjects, which is sufficiently lower than that of the highest dose in the SAD study 
(185 mg) and the projected clinical effective dose (75  mg). 
Therefore, 10  mg as tablet formulation is considered the appropriate starting dose in the MAD 
study.  
The dosing frequency (i.e., QD) was selected  considering the PK characteristics of TCK -276 and 
patien t’s convenience. The dosing duration (7  days) was considered sufficient to achieve steady 
state conditions.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 37 of 98 12 Dec 2022 Dose Escalation  
In this MAD study, the dose escalation progression will be from 10, 25, 75 , and up to 150  mg in 
subsequent  cohorts. The overall exposure to TCK -276 (in terms of geometric mean AUC tau) on 
Day 7  is not expected to exceed the predefined AUC cap . The exposure at 
150 mg dosing in tablet formulation is assumed to be less than the predefined AUC  cap based on 
the results from the SAD study (5  mg to 185  mg, capsule). Therefore,  150 mg is chosen for the 
highest dose. The dose in Cohorts  2, 3, and 4 may be adjusted based on the safety and PK results 
from the previous cohorts, if necessary. Dose escalation will only be allowed after blinded 
assessment of all safety, tolerability, a nd available PK data up to Day  10 from each previous 
cohort evaluated by Investigators, Medical Monitor, and Sponsor representatives during the SRC  
meeting . 
4.4 End of Study Definition  
The end of the study is defined as the date of the last visit of the last pa tient in the study or last 
scheduled procedure shown in the Schedule of Activities ( SoA) (Table  1-1). 
A patient is considered to have completed the study if he/she has completed all periods of the 
study including the last visit.  
5 Study Population  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also k nown as 
protocol waivers or exemptions, is not permitted.  
The study population will consist of patients with RA. Patients must be able to provide written 
consent and meet all the inclusion criteria and none of the exclusion criteria.  
5.1 Inclusion Criteria  
Patients  who meet the following criteria will be considered eligible to participate in the clinical 
study:  
1. Patient voluntarily agrees to participate in this study and signs an Institutional Review Board  
(IRB)  approved informed consent prior to per forming  any of the Screening Visit procedures.  
2. Patient  is able to understand and is willing to comply with all study requirements, and willing  
to follow the instructions  of the study staff.  

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 38 of 98 12 Dec 2022 3. Diagnosis of RA and meeting the 2010 American College of Rheumatol ogy/European 
League Against Rheumatism classification criteria for RA9(total score 6 or greater/10 
diagnosed at least 3 months prior to the Screening  Visit).  
4. Patient  between the ages of 18 and 64 years , inclusive, at the Screening Visit .  
5. Female patient must be not pregnant, not breast feeding and one of the following conditions 
need to apply:  
a. Of non -childbearing potential based on documented surgical treatment (hysterectomy, 
bilateral salpingectomy, bilateral oophorectomy) or post -menopausal, meaning patient 
had spontaneous amenorrhea for at least 12  months without alternate medical cause prior 
to Screening Visit and follicle stimulating hormo ne (FSH)  > 40 U/mL at the Screening 
Visit.  
OR 
b. Of childbearing  potential and using a highly effective method of contraception (failure 
rate of <  1% per year) and agrees to remain on a highly effective method from the time 
of signing the informed consent form  (ICF) until 21 days after the last dose.  
6. Male patient must agree to stay abstinent or must use together with his female partner(s) a 
form of highly effective contraceptive (failure rate of <  1% per year) from the time of signing 
the ICF until up to 3  months after the last dose of the study drug.  
7. Nonsmokers (or oth er nicotine use) as determined by history (no nicotine use over the past 
one year prior to the Screening Visit) and by negative urine cotinine concentration 
(< 200 ng/mL) at the Screening Visit and at Admission.  
8. Body mass index (BMI) between 18.5 and 32.0  kg/m2, inclusive, at the Screening Visit.  
9. Patient  is required to have completed a COVID -19 vaccine regimen within no more than 
5 months prior to screening to be eligible for the study.  
10. Permitted concomitant medications for any reason, must be on a stable dose (12  weeks for 
methotrexate and anti-malarials  and at least 30  days for other medications prior to the 
Screening Visit).   
Permitted medications  include : anti -malarials; nonsteroidal anti-inflammatory drugs 
including selective cyclooxygenase -2 inhibitors at approved dosage, and low dose oral 
corticosteroids (prednisone ≤  10 mg/day or equivalent ); methotrexate ≤  25 mg by mouth 
(PO) or subcutaneous (SC) weekly concomitantly with folic ac id or folinic acid . 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 39 of 98 12 Dec 2022 5.2 Exclusion Criteria  
Patients who meet one or more of the following criteria will not be considered eligible to 
participate in the clinical study:  
1. Female patients who are breastfeeding or have a positive urine pregnancy test either at the 
Screening Visit or at Admission.  
2. Patients  who are unable to eat the prescribed meals during the stay at the site; vegetarian  or 
vegan.  
3. Patient  has a history of significant drug allergy, as determined by the Investigator.  
4. Patient has used a study drug , any prohibited medication(s) (see Section  6.8.2 ), 
over-the-counter ( OTC ) medications, vitamins, dietary and herbal supplements  within 
14 days or 5  half-lives if known (whichever is longer)  prior to the first dose of study drug.  
5. Patient has a history of active suicidal ideation in the past 6  months prior to the Screening  
Visit, or any psychiatric disorders that will affect the patient’s ability to participate in the 
study as determined by the Investigator.  
6. Patient has a current or recent (within 14  days prior to the Screening Visit) history of 
uncontrolled, clinically sig nificant infectious, hematological, renal, endocrine, pulmonary, 
gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease . 
7. Patient with any of the following laboratory abnormalities either at the Screening Visit or at 
Admissi on. These assessments may be repeated once at the discretion of the Investigator.  
a. Aspartate aminotransferase  (AST), alanine aminotransferase (ALT) ≥  2 times the upper 
limit of normal (ULN)  
b. Bilirubin ≥  1.5 times ULN  
c. An estimated glomerular filtration rate  (eGFR) according to Cockcroft -Gault 
≤ 60 mL/min  
d. Hematology values below the lower limit of normal : Neutropenia, absolute neutrophil 
count <  1000/mm3, hemoglobin  < 9 g/dL, white blood cell  < 2.5 × 103/μL 
e. Clinically significant abnormalities, as judged by the Investigator  
8. Patient has a history of alcohol and/or drug abuse within 24  weeks of the Screening Visit.  
9. Patient has positive results for drug testing either  at the Screening Visit or at Admission.  
10. Patient has positive breath alcohol test either at the Screening Visit or at Admission.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 40 of 98 12 Dec 2022 11. Regular consumption of alcohol within 6  months prior to the Screening Visit 
(> 7 drinks/week for females, >  14 drinks/week for males where 1  drink  = 5 ounces [150  mL] 
of wine or 12  ounces [360  mL] of beer or 1.5  ounces [45  mL] of hard liquor), or use of drugs 
of abuse (such as marijuana) within 3  months prior to the Screening Visit.  
12. Patient has positive test for h epatitis B surface antigen  (HBsAg), anti -hepatitis B core  (HBc) 
antibodies, hepatitis C virus (HCV) antibody, and/or h uman immunodeficiency virus  (HIV) 
antibody at Screening Visit.  
13. Patient has QT interval corrected for heart rate (QTc) using Fridericia’s correction (QTcF) 
> 450 ms for males or QTcF >  470 ms for f emales either at the Screening Visit or Admission, 
based on safety 12 -lead electrocardiogram ( ECG ). Patient has Screening or Admission ECG 
with second - or third -degree atrioventricular block, bundle branch block, arrhythmia (but not 
sinus arrhythmia or sup raventricular premature beats), or illegible QT interval.  
14. Patient  has history or evidence of cardiopathy, acute coronary syndrome, hypertrophic 
cardiomyopathy, myocarditis or QT prolongation syndrome.  
15. Patient is unwilling to abstain from drinks and foods containing alcohol, grapefruit, or 
caffeine (including coffee, tea, coke, energy drinks, or chocolate) starting 72  hours prior to 
the Admission until Day  14 Follow -up Visit. 
16. Patient has donated blood or  experienced acute blood loss (including plasmapheresis ) of 
greater than 500  mL within 90  days prior to the first dose of study drug.  
17. Patients  with a known immunodeficiency disorder. Have a history of a major organ transplant 
or hematopoietic stem cell/mar row transplant.  
18. Patients with infections requiring treatment or hospitalization within 14  days prior to the 
Screening Visit, parenteral antimicrobial therapy within 60  days prior to the Screening Visit, 
infected joint prosthesis; history of herpes zoster, active herpes simplex, or herpes simplex on 
suppressive therapy.  
19. Patient has a chronic hepatic disease or hepatic impairment.  
20. Patient has a history of  Mycobacterium tuberculosis  or positive interferon gamma release 
assay for tuberculosis  (IGRA -TB) or abnor mal chest X -ray (for positive IGRA -TB patients) 
at the Screening Visit.  
21. Patient has a history of any lymphoproliferative disorder.  
22. Patient has a history of  COVID -19 unless fully recovered with no sequalae for 14  days.  
23. Patient who had a severe course of COVID -19 (extracorporeal membrane oxygenation, 
mechanically ventilated).  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 41 of 98 12 Dec 2022 24. Patient who has recent (within 14  days prior to the Screening Visit or between the Screening 
Visit and Admission) exposure to someone who has COVID -19 symptoms or positive test 
result . 
25. Patient who has a positive reverse transcription polymerase chain reaction (RT -PCR) test for 
SARS -CoV-2 either at the Screening Visit or at Admission.  
26. Patient who has clinical signs and symptoms consistent with SARS -CoV-2 infection; e.g., 
fever, dry coug h, dyspnea, sore throat, fatigue, or positive SARS -CoV-2 test result within 
14 days prior to and including either the Screening Visit or Admission.  
27. Patients may not receive any live/attenuated vaccine from 30  days prior to the Screening 
Visit until Day  14 Follow -up Visit.  
28. COVID -19 vaccine should not be given 1  week prior to the Screening Visit.  
29. Patients treated with any other medications listed under Inclusion Criteria #9 including all 
medications listed in Section 6.8.2 . 
30. Patients with malignancy or history of malignancy except adequately treated or excised 
non-metastatic basal cell or squamous cell cancer of the  skin or cervical carcinoma in situ.  
Previous  treatment with total lymphoid  irradiation.  
31. History of recurrent inflammatory joint disease other than RA (e.g., gout, Lyme disease) or 
history of any other autoimmune rheumatic diseases other than Sjogren’s syn drome.  
32. Major surgery within 30  days prior to the Screening Visit or patients with planned surgery.  
33. Patients who have an abnormal chest X -ray for interstitial lung disease (ILD) at the 
Screening Visit and/or patients with history of ILD. 
34. History of fainting or family history of sudden death.  
35. Patient has any disorder that would interfere with the absorption, distribution, met abolism or 
excretion of study drug.  
36. Patient has a history of deep vein thrombosis and/or pulmonary embolism.  
37. Patient has poor venous access.  
38. Patient is an employee of the clinical research team (any Teijin or research site employee) or 
has a family member who is an employee of these organizations.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 42 of 98 12 Dec 2022 39. Patient is unable to understand the protocol requirements, instructions, study related 
restrictions, nature, scope, and possible consequences of the clinical study. Patient is unlikely 
to comply with the protocol requirements, instructions and study related restrictions; e.g., 
uncooperative attitude, inability to return for Follow -up Visits and improbability of 
completing the clinical study.  
40. Patient is judged as inappropriate for study participation by the Investi gator for other reasons.  
5.3 Lifestyle Considera tions  
5.3.1 Meals  and Dietary Restrictions  
Refrain from consumption of grapefruit foods or beverages, or Seville -orange containing foods 
(e.g., orange marmalade) or beverages from 72 hours  before  Admission until Day 14. 
5.3.2 Caffeine, Alcohol, and Tobacco  
1. During each dosing session, patient will abstain from ingesting caffeine - or 
xanthine -containing products ( e.g., coffee, tea, cola drinks , and chocolate) for 72 hours  
before Admission until Day 14. 
2. During each dosing session, patients will abstain from alcohol and alcohol -containing foods, 
medications , or beverages  for 72 hours  before Admission until Day 14. 
3. Patients who use tobacco products will be instructed that use of nicotine -containing products 
(snuff, chewing tobacco, cigars, pipes , vaping t obacco products or nicotine -replacement 
products such as nicotine chewing gum and nicotine plasters ) will not be permitted  from 
1 year before the Screening Visit until  Day 14. 
5.4 Screen Failures  
A screen  failure occurs when a patient  who consent s to participate in the clinical study  is not 
subsequently randomly assigned to study intervention . A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure patient s to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond 
to queries from regulatory authorities. Minimal information includes demography, reason for 
screen failure (e.g., eligibility requirements failed),  and documentation of any medical 
occurrences that qualify as SAE s. 
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened  once . Rescreened patient s should be assigned a new  patient  number for every 
Screeni ng/Rescreening event . 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 45 of 98 12 Dec 2022 or will be destroyed locally in agreement with the Sponsor and Certificates of Destruction 
provided to the Sponsor.  
Further guidance and information for the final disposition of unused study intervention  are 
provided in the study reference manual or other specified location.  
6.3 Measures to Minimize Bias: Randomization and Blinding  
Table  6–3 Measures to Minimize Bias  
Study using IRT All patients will be centrally randomized using an IRT. Each pa tient will 
be assigned a unique number (randomization number) that encodes the 
patient’s assignment to a treatment group within one of the 4 cohorts  of 
the study, according to the randomization schedule ge nerated by IRT 
using a validated computer program. Details of the procedure are 
described in the IRT Manual provided to all sites.  
Study intervention  will be administered/ dispensed at the study visits  as 
summarized in the SoA ( Table  1-1). 
Returned study intervention should not be re -dispensed to the pa tients . 
Blind break 
(IRT) This is a double -blind study in which patients/care 
providers/ Investigators/outcomes assessors, are blinded to study 
intervention. The IRT will be programmed with blind -breaking 
instructions. In case of an emergency, the Investigator has the sole 
responsibility for determining  if unblinding of a patien t’s study  
intervention  assignment is warranted. Pa tient safety must always be the 
first consideration in making such a determination. If the Investigator 
decides that unblinding is warranted, the Investigator should make every 
effort to contact the Sponsor prior to unblinding a patient’s study  
intervention  assignment unless this could delay emergency treatment for 
the pa tient. If a patient’s study  intervention  assignment is unblinded, the 
Sponsor  must be notified within 24 hours of this occurrence . The date and 
reason for the unblind ing must be recorded.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 46 of 98 12 Dec 2022 Blinded study 
with unblinded 
third party  who 
is dispensing 
intervention  Patients will be randomly assigned in a 3:1 ratio to receive study 
intervention. Investigators will remain blinded to each patient’s assigned 
study intervention throughout the course of the study. To maintain this 
blind, an otherwise uninvolved third party will be responsible for the 
reconstitution and dispensation of all study intervention and will endeavor 
to ensure that there are no differences in time taken to dispense following 
randomization.  
This third party will instruct the pa tient/patient’s LAR  to avoid discussing 
the taste, dosing frequency , or packaging of the study intervention with 
the Investigator.  
In the event of a quality assurance audit, the auditor(s) will be allowed 
access to unblinded study intervention records at the site(s) to verify that 
randomization/dispensing has been conduct ed accurately.  
IRT = Interactive Response Technology ; LAR  = legally authorized representative.  
Sponsor safety staff may unblind the intervention assignment for any pa tient with an SAE.  If the 
suspected unexpected serious adverse reaction ( SUSAR ) requires that an expedited regulatory 
report be sent to one or more regulatory agencies, a copy of the report, identifying the patient’s 
intervention assignment, may be sent to Investigators in accordance with local regulations and/or 
Sponsor policy.  
6.4 Stud y Intervention  Compliance  
When pa tients are dosed at the site, they will receive study intervention directly from the 
Investigator or designee, under medical supervision. The date and time of each dose administered 
in the clinic will be recorded in the sou rce documents. The dose of study intervention and study 
patient identification will be confirmed at the time of dosing by a member of the study site staff 
other than the person administering the study intervention.  
6.5 Dose Modification  
The dosing schedule ma y be adjusted based on the safety and PK results, if necessary,  to expand 
a dosing cohort to further evaluate safety, and/or PK findings at a given dose level or to add 
cohorts to evaluate  additional dose levels. The study procedures for these additional 
patient(s)/cohort(s) will be the same as that described for other study patients/cohorts . 
6.6 Continued Access to Study Intervention After the End of the Study  
Study intervention for RA will not continue beyond this study.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 47 of 98 12 Dec 2022 6.7 Treatment of Overdose  
For this study , any dose of TCK -276 greater than 10 mg (Cohort  1), 25 mg (Cohort  2), 75 mg 
(Cohort  3), and 150  mg (Cohort  4) within a 24 -hour time period will be considered an overdose.  
The Sponsor does not recommend specific treatment for an overdose . 
In the event of an overdose, the Investigator should:  
a. Contact the Medical Monitor immediately.  
b. Evaluate the patient  to determine, in consultation with the Medical Monitor , whether 
study intervention should be interrupted or whether the dose should be reduc ed. 
c. Closely monitor the patient  for any AE/SAE and laboratory abnormalities until TCK -276 
can no longer be detected systemically.  
d. Obtain a plasma sample for PK analysis if requested by the Medical Monitor (determined 
on a case -by-case basis ). 
e. Document the quantity of the excess dose as well as the duration of the overdose . 
6.8 Concomitant Therapy  
Any medication  or vaccine (including OTC  or prescription medicines, recreational drugs, 
vitamins, and/or herbal supplements)  or other specific categories of interest  that the patient  is 
receiving at the time of enrollment or receives during the study must be recorded along with:  
a. reason for use  
b. dates of administration including start and end dates  
c. dosage information including do se and frequency  
The Medical Monitor should be contacted if there are any questions regarding concomitant or 
prior therapy  before the Investigators initiate the therapy . 
6.8.1 Permitted Medications  
Permitted medication includes anti-malarials nonsteroidal anti -inflammatory drugs including 
selective cyclooxygenase -2 inhibitors at approved dosage, low dose oral corticosteroids 
(prednisone ≤  10 mg/day or equivalent); methotrexate ≤  25 mg PO or SC weekly concomitantly 
with folic acid  or folinic acid . 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 48 of 98 12 Dec 2022 6.8.2 Prohibited Medic ations  
Prohibited medications may include, but are not limited to, those listed in Appendix  6 
(Section  10.6). These listings of prohib ited concomitant treatments are not considered all 
inclusive. If the use of these types of medications is medically necessary during the course of the 
study, the Investigator must contact the Sponsor Medical Monitor to discuss further 
administration of TCK -276. A decision to allow the patient to continue in the study will be made 
on a case -by-case basis.  
6.8.2.1  Caution  
 
 Investigators should recognize potential 
interactions with these drugs and avoid maximum doses, if possible, if these drugs are used.  
Cautioned medications may include, but are not limited to, those listed i n Appendix  6 
(Section  10.6). These listings of cautioned concomitant treatments are not considered al l 
inclusive.  
7 Discontinuation of Study Intervention and Patient  Discontinuation  
7.1 Discontinuation of Study Intervention  
It may be necessary for a pa tient to permanently discontinue study intervention. If study 
intervention is permanently  discontinued, the pa tient will remain in the study to be evaluated for 
clinical observation and safety monitoring . See the SoA  (Table  1-1) for data to be collected at the 

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 49 of 98 12 Dec 2022 time of discontinuation of study intervention and follow -up and for any further evaluations that 
need to be completed.  
7.1.1 Overall Study Stopping Criteria  
The study will be stopped if any of the following occur and are thought to be at least possibly 
related to study intervention  agreed upon by the SRC:  
• Two patients develop the same Grade 3 AE (grading is based on the Common Terminology 
Criteria for  Adverse Events [CTCAE] version 5.0).  
• One patient develops ≥  Grade 4 AE (CTCAE version 5.0).  
• Death  of a patient at any time.  
If any of the following  scenarios occur within a cohort with reasonable possibility of a causal 
relationship with study drug, dos ing will be stopped, and further dosing will not be initiated.  
• One or more patients experience increased alanine ALT or AST >  3 × ULN with total 
bilirubin (TBL) >  2 × ULN or increased AST >  3 × ULN accompanied by alkaline 
phosphatase  (ALP) >  1.5 × ULN.  
• One or more patient s experience a decrease of absolute neutrophil count less than 
1,000/mm3 or white blood cell (WBC) less than 2.5  × 103/μL or platelet count less than 
75,000/μL.  
• One or more patients have an increase of more than 60 ms in QTcF compared to th e baseline 
QTcF (baseline QTcF  = value obtained on Day 1 at pre -dose in the treatment period) or 
QTcF >  500 ms or other clinically significant conduction disturbance or arrhythmia. All 
ECGs for this determination must be performed under strict resting conditions.  
• Two or more patients, who receive study intervention , have tachycardia defined as resting 
supine heart rate >  125 beats per minute (bpm) persisting for at least 10  minutes.  
• Two or more patients, who receive study intervention , have symp tomatic bradycardia 
defined as resting supine heart rate <  40 bpm accompanied with symptoms of bradycardia 
while awake persisting for at least 10 minutes.  
• Two or more patients, who receive study intervention , develop hypertension defined as an 
increase in resting supine systolic blood pressure (BP) >  40 mmHg to above a reading of 180 
mmHg and persisting for at least 10  minutes.  
If the criteria were met, the SRC will carefully review the totality of data, considering moderate 
non-serious AEs at least possibl y related to the study intervention  administration in unblinded 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 50 of 98 12 Dec 2022 fashion,  the number of patients in which they occur, concurrency of more than one within the 
same patient. Although changes  from normal ranges  are most relevant, changes from baseline 
measurem ents will also considered observing any trends.  If consensus among the voting SRC 
members cannot be reached, then the Principal Investigator, who has the ultimate responsibility 
for the safety of the patient s, will make the final decision.  
7.1.2 Dose Escalation  
After each sub-cohort and cohort, the Principal Investigator  and the SRC  will evaluate the safety, 
tolerability data and available PK data up to Day  10 to determine the next dose. The predefined 
AUC tau  level will be used in the SRC as a 
benchmark so that the human exposure can be compared with preclinical exposure data. The 
safety and PK data from all patients in the previous cohort must be reviewed before a decision to 
escalate the dose can be made. Dos e escalation will only occur if data from a minimum of 
6 patients have been reviewed from the previous lower dose group, such that data from a 
minimum of 4  patients who have received active treatment will be used to make the dose 
escalation decision (based  on the randomization of 6  active  treatment :2 matching placebo).  
Doses will not exceed a dose level at which the geometric mean of  AUC tau exceeds or would be 
anticipated to exceed the following limits : 
  
 
 
 
If PK data indicate that the predefined AUC  has 
been achieved or would be exceeded with escalation to the next higher dose, dose escalation will 
be stopped. A dose in which the stopping criteria ha ve been met will not be repeated and further 
dose escalation will not occur. Where stopping criteria have not been met, the decision of the 
SRC may be to give the next intended dose, a smaller than the predefined dose increment, a 
repeated dose or to stop dosing. The SRC will make the decision for the next dose level (to give 
the next intended dose, a greater or smaller dose increment than the intended dose, a repeated 
dose) or whether to stop the study after reviewing all the pertinent safety and any other  relevant 
data and decision of the voting members. If consensus among the voting SRC members cannot 
be reached then the Principal Investigators , who have  the ultimate responsibility for the safety of 
the patients, will make the final decision on the next d ose level or whether to stop the study. In 
any event, dose escalation can only occur if agreed by the Principal Investigators . The decisions 
of the SRC on the next dose level will be documented and provided to all the appropriate parties 

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 51 of 98 12 Dec 2022 involved with the study, including the pharmacist to enable study intervention preparation for the 
next scheduled dosing day.  
Initially the data will be reviewed blinded, but if the Principal Investigators or the SRC consider 
it necessary due to a safety concern, either individual patients or the entire cohort may be 
unblinded to enable decision making. Before breaking the code, the potential decisions and 
actions should be determined. The code will be broke n according to local standard operating 
procedures ( SOPs ). Following review of data from a cohort of patients, the timing of assessments 
and/or blood samples may be adjusted for subsequent cohorts.  
Dose escalation will be stopped if any of the following oc cur and are thought to be at least 
possibly related to study intervention  agreed upon by the SRC. It is determined that the limit of 
safety and/or tolerability has been reached as determined by the SRC.  
• Two or more of the patients in a cohort develop ≥  Grade 2 AEs (CTCAE version 5.0) in the 
same category, related to TCK -276, as judged by the Investigator.  
• One or more patients in a cohort develop ≥  Grade  3 AEs (CTCAE version 5.0) in the same 
category, related to TCK -276, as judged by the Investigator.  
7.2 Patient Discontinuation /Withdrawal  from the Study  
A patient may withdraw from the study at any time at their own request or  may be withdrawn at 
any time at the discretion  of the I nvestigator  for safety, behavioral , or compliance  reasons . The 
patient will be permanently discontinued from the study intervention and the study at that time.  
If the patient  withdraws consent  for disclos ure of future information, the Sponsor may retain and 
continue to use any data collected before such a withdrawal of consen t. 
If a patient  withdraws from the study, he/she may request destruction of any samples taken and 
not tested , and the Investigator must document this in the site study records . 
At the time of discontinuing from the study, if possible, an early discontinuat ion visit should be 
conducted, as shown in the SoA  (Table  1-1). Refer to the SoA for data to be collected at the time 
of study discontinuation and follow -up and for any further evaluations that need to be completed.  
In addition  to the stopping rules desc ribed in Section  7.1.1 , a patient will be withdrawn by the 
Investigator or designee from the study and not be allowed to continue with the study if any of 
the following criteria are fulfilled:  
• Any patient who develops an AE ≥  Grade  3 (CTCAE version 5.0) .  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 52 of 98 12 Dec 2022 • Patient  will be discontinued from further dosing if following toxicities are observed:  
o Hematologic: Neutropenia, absolute neutrophil count <  1000/mm3, 
hemoglobin  < 9 g/dL, white blood cell  < 2.5 × 103/μL 
o Renal : serum creatinine > 3  × ULN  
o Hepatic : bilirubin elevation  > 2 × ULN; AST or ALT elevation  > 3.0 × ULN  
o QTcF prolongation : mean QTcF  ≥ 500 ms or change from the nearest baseline  > 60 ms 
o ECG abnor malities  including ventricular tachycardia or ventricular fibrillation, complete 
heart block (Grade III atrioventricular  block) or second degree atrioventricular  block 
Mobitz type  II  
o Hypertension : resting systolic BP  ≥ 180 mmHg and ≤ 80 mmHg diastolic BP   
Hypotension: resting systolic BP  ≥ 110 mmHg and ≤ 40 mmHg diastolic BP  
o Pulse ( resting ) < 35 or >  110 bpm  
• A patient may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the Investigator for saf ety, behavioral or 
administrative reasons.  
• If the patient withdraws consent for disclosure of future information, the Sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.  
• If a patient withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the Investigator must document this in the site study records.  
• Withdrawn patients may be replaced if patient withdrawal is not due to safety or tolerability 
reasons.  
• Refer to the SoA for assessments to be performed at the time of study discontinuation.  
o At the discretion of the Investigator or designee, the patient may continue with study 
assessments after discontinuation until the final Follow -up Visit procedures are 
performed. A reasonable effort will be made to determine the reasons why a patient fails 
to return for the necessary visits or is discontinued from the study. If the patient is 
unreachable by telephone, a registered letter, at the min imum, should be sent to the 
patient requesting him/her to contact the study center.  
While patients are encouraged to complete all study evaluations, they may withdraw from the 
study at any time and for any reason. Every effort will be made to determine why  any patient 
withdraws from the study prematurely. All patients who withdraw from the study with an 
ongoing AE must be followed until the event is resolved or deemed stable. If a patient withdraws 
prematurely after dosing, all data to be collected prior to  discharge from the clinical site should 
be collected at the time of premature discontinuation or at the scheduled discharge.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 53 of 98 12 Dec 2022 Patient participation may be terminated prior to completing the study and the reason recorded as 
follows:  
1. Adverse event  
2. Protocol violation  
3. Loss to follow -up  
4. Patient  withdrew consent at own request  
5. Other  
A genuine effort must be made to determine the reasons why a patient fails to return for the 
necessary visits or is discontinued from the study. If the patient is unreachable by t elephone, a 
registered letter, at the minimum, should be sent to the patient requesting him/her to contact the 
clinic.  
Patients who are withdrawn after randomization for non -drug-related reasons may be replaced 
following discussion between the Investigator  and the Sponsor. Patients withdrawn after 
randomization as a result of AEs thought to be related to the study drug will generally not be 
replaced.  
7.3 Lost to Follow -Up 
A patient will be considered lost to follow -up if they repeatedly fail to return for scheduled visits 
and are unable to be contacted by the study site.  
The following  actions must be taken if a patient fails to return to the clinic for a required study 
visit:  
a. The site must attempt to contact the patient and re schedule the m issed visit as soon as 
possible (and within the visit window, where one is defined) , counsel the patient on the 
importance of maintaining the assigned visit schedule , and ascertain whether the patient 
wishes to and/or should continue in the s tudy.  
b. In cases in which the patient is deemed lost to follow -up, the I nvestigator or designee 
must make every effort to regain contact with the patient  (where possible, 3 telephone 
calls and , if necessary , a certified letter to the patient’s last known mailing address or 
local equivalent methods). These contact attempts should be documented in the patient ’s 
medical record /case report form ( CRF ). 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 54 of 98 12 Dec 2022 c. Should the patient continue to be unreachable, he/she will be considered to  have 
withdrawn from the study.  
d. Site personnel, or an independent third party, will attempt to collect the vital status of the 
patient  within legal and ethical boundaries for all patient s randomized, including those 
who did not get study inter vention. Public sources may be searched for vital status 
information.  If vital status is determined as deceased, this will be documented and the 
patient  will not be considered lost to follow -up. Sponsor personnel will not be involved in 
any attempts to col lect vital status information . 
8 Study Assessments and Procedures  
Study procedures  and their timing are summarized in the SoA  (Table  1-1). Protocol waivers or 
exemptions are not allowed.  
A Safety Management Plan (SMP) will be signed between the Sponsor and .  
Immediate  safety concerns should be discussed with the Sponsor immediately upon occurrence 
or awareness to determine if the patient  should continue or discontinue study intervention.  
Adherence  to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct.  
All scree ning evaluations must be completed and reviewed to confirm that potential patient s 
meet all eligibility criteria. The Investigator  will maintain a screening log to record details of all 
patient s screened and to confirm eligibility or record reasons for scr eening failure, as applicable.  
Procedures conducted as part of the patient ’s routine clinical management ( e.g., blood count) and 
obtained before  signing of the ICF may be used for screening or baseline purposes provided the 
procedures met the protocol -specified criteria and were performed within the timeframe defined 
in the SoA.  
Safety/ laboratory /analyte results that could  unblind the study will not be reported to investigative 
sites or other blinded personnel until the study has been unblinded.  
The maximum amount of blood collected from each patient  over the duration of the study, 
including any extra assessments that may be required , will not exceed 600  mL  
Blood samples  of approximately 520 mL will be collected for measurement  of blood 
concentra tions of TCK -276 and TEI -W00595 as specified in the SoA ( Table  1-1) throughout the 
study period . A maximum of 30  samples may be collected at additional t imepoints during the 

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 55 of 98 12 Dec 2022 study if warranted and agreed upon between the Investigator and the Sponsor. The timing of 
sampling may be altered during the course of the study based on newly available data (e.g., to 
obtain data closer to the time of peak plasma con centrations) to ensure appropriate monitoring. 
Instructions for the collection and handling of biological samples will be provided by the 
Sponsor. The actual date and time (24 -hour clock time) of each sample will be recorded.  
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the 
samples.  
8.1 Administrative Procedures  
8.1.1 Informed Consent  
Informed consent must be documented according to  Appendix  1 (Section  10.1.3 ).  
8.1.2 Patient  Identification Card  
All pa tients will be given a pa tient identification card identifying them as pa tients in a research 
study. The card will contain study site contact information (including direct telephone numbers) 
to be used in the event of an emergency. The Investigator or qualified designee will provide th e 
patient with a pa tient identification card immediately after the pa tient provides written informed 
consent. At the time of intervention allocation/randomization, site personnel will add the 
intervention/randomization number to the p atient  identification card.  
8.1.3 Calibration of Equipment  
The Investigator (or qualified designee) is responsible for ensuring that any device or instrument 
used for a clinical evaluation/test during the study that provides information about eligibility 
criteria and/or safety or eff icacy parameters is suitably calibrated and/or maintained to ensure 
that the data obtained are reliable and/or reproducible. Documentation of equipment calibration 
must be retained as source documentation at the study site.  
8.2 Screening and Eligibility Assess ments  
8.2.1 Eligibility Criteria  
All inclusion and exclusion criteria (Section 5.1 and Section  5.2) will be reviewed by the 
Investigator or designee to ensure that the patient qualifies for the study. Recheck of clinical 
status will need to be performed before the first dose of study intervention.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 56 of 98 12 Dec 2022 8.2.2 Demography  and Other Baseline Information  
The following demographic information will be recorded:  
• Age 
• Ethnic origin (Hispanic/Latino or not Hispanic/not Latino)  
• Race (White, American Indian/Alaska Native, Asian, Native Hawaiian or other Pacific 
Islander, Black/African American)  
• Height, without shoes (cm)  
• Body weight, without shoes (kg)  
• Body mass index (BMI) (kg/m2) 
Other baseline characteristics will be recorded as follows:  
• History of drug abuse  
• History of alcohol abuse  
• Smoking history  
• History of caffeine use (or other stimulating beverages)  
• Special diet (vegetarian  and vegan ) 
• History of blood or plasma donation  
8.2.3 Medical History  
A medical history will be obtained by the Investigator or qualified designee. The medical history 
will collect al l active conditions and any condition diagnosed within the prior 1 year that the 
Investigator considers to be clinically relevant. Details regarding the disease for which the 
patient has enrolled in this study will be recorded separately and not listed as medical history.  
• The medical history comprises:  
• General medical history  
• Medication history  
• Prior and concomitant medication  
• Reproductive history  
• Onset date of RA  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 57 of 98 12 Dec 2022 • Criteria for the classification of RA used for the diagnosis  
• History of surgery of RA  
• Name of the RA treatment drugs used in the past  
8.2.4 Prior and Concomitant Medications Review  
The Investigator or qualified designee will review prior medication use and record prior 
medications taken by the patient.  
The Investigator or qualified designee will record medication, if any, taken by the patient during 
the study through the last visit. Concomitant medications will be recorded until the last dose of 
study intervention (or longer if related to an SAE).  
8.2.5 Screening Assessments  
Patients who have signed an informed consent will undergo following procedures and 
assessments:  
• Viral serology to HBsAg, anti -HBc antibodies, anti -HCV antibody, and/or anti -HIV types  1 
and 2 antibodies  
• Blood and urine drug screen to check the levels of amphetamines, barbiturates, 
benzodiazepines, oxycodone, tricyclic antidepressants, cannabinoids, cocaine, opiates, 
phencyclidine, 3,4 -Methylenedioxymethamphetamine  (MDMA) and propoxyphene  
• Breath alcohol test by breathalyzer  
• Interferon gamma release assay for tuberculos is (IGRA -TB) or abnormal chest X -ray 
• Urine cotinine test  
• SARS -CoV-2 test measured by real time RT-PCR  
• Classification of disease stage/progression of RA  
• For female patients, a urine β -human chorionic gonadotropin test must be used to confirm 
eligibility  
• For female patients who are post -menopausal, FSH levels will be measured  
Laboratory tests are listed in  Table  10–1. 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 58 of 98 12 Dec 2022 8.3 Safety Assessments  
Planned timepoint s for all safety assessments are provided in the SoA  (Table  1-1). 
8.3.1 Physical Examinations  
Physical examinations will be performed at the time points detailed in the SoA ( Table  1-1). 
Full physical examination : 
An assessment of general appearance and a review of systems (dermatologic, head, eyes, ears, 
nose, mouth/throat/neck, thyroid, lymph nodes, respiratory, cardiovascular, gastrointestinal, 
extremities, musculoskeletal, neurologic , and psychiatric systems).  
Brief physical examination:  
An assessment  of the general appearance, skin, cardiovascular system, respiratory system , and 
abdomen.  
The brief physical examination may be extended to a full physical examination if considered 
necessary by the Investigator s. Othe r evaluations may be performed as deemed necessary by the 
Investigator s. 
Investigators should pay special attention to clinical signs related to previous serious illnesses.  
8.3.2 Vital Signs  
Vital signs will be assessed at the time points detailed in the SoA ( Table  1-1). The following vital 
signs will be measured:  
• Blood pressure (systolic and diastolic [mmHg])  
• Pulse (bpm)  
• Body temperature (tympanic [ear] or non -contact infrared thermometers) (°C) 
• Respiratory rate (breaths per minute)  
Supine BP and pulse recordings will be made after the patient has been recumbent and at rest 
≥ 5 minutes.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 59 of 98 12 Dec 2022 8.3.3 Electrocardiograms  
Standard safety 12 -lead ECGs will be performed at the time points detailed in the SoA 
(Table  1-1). 
The12-lead ECGs  will be performed after the patient has been resting supine for ≥  5 minu tes. 
The ECG will include all 12 standard leads and a Lead II rhythm strip on the bottom of the 
tracing. The ECG will be recorded at a paper speed of 25 mm/sec. The following ECG 
parameters will be collected: PR interval, QRS interval, RR interval, QT inte rval and QTc 
interval  (QTcF) . 
All ECGs must be evaluated by a qualified physician for the presence of abnormalities.  
8.3.4 Cardiac Telemetry  
To allow a real -time assessment of cardiac safety at the study site, patients will be monitored by 
cardiac telemetry (for real -time assessment of cardiac rate and rhythm). Any clinically 
significant change noted on telemetry will be followed up with a 12 -lead ECG. Further 
evaluation and treatment will be performed as deemed appropriate by the Investigator s. 
Irrespective of the intervention, the ECG and continuous cardiac monitoring will be repeated 
hourly until the event resolves or the patient is deemed clinically stable by the Investigator s. 
8.3.5 Clinical Safety Laboratory Tests  
Refer  to Appendix  2 (Section 10.2) for the list of clinical laboratory tests to be performed and the 
SoA (Table  1-1) for the timing and frequency.  
The Investigator  must review the laboratory report, document this review, and record any 
clinically significant  changes occurring during the study as an AE . The laboratory reports must 
be filed with the source documents . 
Abnormal  laboratory findings associated with the underlying disease  are not considered 
clinically significant  unless judged by the Investigator to be more severe than expected for the 
patient ’s condition.  
All laboratory tests with values considered clinically abnormal during participation in the study 
or within  2 months  after the last dose of study intervention s hould be repeated until the values 
return to normal or baseline  or are no longer considered clinically significant by the Investigator  
or Medical Monitor . 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 60 of 98 12 Dec 2022 a. If clinically significant/any  values do not return to normal/baseline within a period of 
time judged reasonable by the Investigator, the etiology should be identified, where 
possible, and the Sponsor notified.  
b. All protocol -required laboratory tests, as defined in Appendix  2 (Section 10.2), must be 
conducted in accordance with the  laboratory manual and the SoA  (Table  1-1). 
c. If laboratory values from laboratory tests not specified in the protocol and performed at 
the institution’s local laboratory result in the need for a change in patient  management or 
are considered clinically relevant by the Investigator ( e.g., are considered to be an SAE or 
an AE or require dose modification), then the resul ts must be recorded.  
8.3.6 Pregnancy Testing  
Women of non -childbearing potential should only be include d after a confirmed negative urine 
pregnancy test s at Screening and on Day  - 1. 
Women of childbearing potential should only be included  after a confirmed negative urine 
pregnancy test at Screening, Days -1 and 14 , and Earl y termination procedures . 
8.4 Adverse Events , Serious Adverse Events , and Other Safety Reporting  
The means of obtaining AE data should be described (volunteered, checklist, or questioning) as 
should any specific rating scales used and any specifically planned follow -up procedures for AEs 
or any planned re-challenge  procedure s. 
Consider whether there any protocol -specific events that may need expedited reporting , or 
alternatively , are not required to be reported . Provide guidance for Investigators . If there is a 
specific AE that will be of special interest it should be described in Section  8.4.6 . 
The definitions of AE s and SAE s can be found in Appendix  3 (Section 10.3). 
AEs will be reported by the patient  (or, when appropriate, by a caregiver, surrogate, or a legally 
authorized representative  [LAR] ). 
The Investigator and any qualified designees are responsible for detecting, documenting , and 
reporting events that meet the de finition of an AE or SAE and remain responsible for following  
up AE that are serious, considered related to the study intervention  or the study, or that caused 
the patient to discontin ue the study intervention  (see Section  7). 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 61 of 98 12 Dec 2022 The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are pr ovided in Appendix  3 
(Section  10.3). 
Screening form including AE questioning will include specific questions regarding symptoms of 
COVID -19: fever, cough, dry throat, difficulty breathing, and potential exposure in the past 
2 weeks.  
Confirmed and suspected SARS -CoV-2 infection and COVID -19 will be recorded in the AE 
fields.  
8.4.1 Time Period and Frequency for Collecting Adverse Events and Serious 
Adverse Events  Information  
All AEs and SAEs will be collected and recorded for each patient from the date for signing of 
ICF until Day 14 Follow -up Visit or early termination visit i.e., the pat ient has discontinued or 
completed Day 14 visit  in the SoA  (Table  1-1). 
All SAE s will be recorded and reported to the Sponsor  or designee within 24  hours  of awareness , 
as indicated in  Appendix  3 (Section  10.3). The Investigator will submit any updated SAE data to 
the Sponsor  within 24 hours of it being available.  
Investigators are no t obliged to actively seek information on AEs or SAE s after the conclusion of  
study participa tion. However, if the Investigator learns of any SAE, including a death, at any 
time after a patient  has been discharged from the study, and he/she considers the event to be 
reasonably related to the study intervention  or study participation, the Investigator must promptly 
notif y the Sponsor . 
8.4.2 Method of Detecting Adverse Events and Serious Adverse Events  
Care will be taken not to introduce bias when detecting AE s and/or SAE s. Open -ended and 
non-leading verbal questioning of the patient  is the preferred method to inquire about 
AE occurrence.  
8.4.3 Follow -up of Adverse Events  and Serious Adverse Events  
After the initial AE/SAE report, the Investigator is required to proactively follow each patient  at 
subsequent visits/contacts.  All SAE s, and no n-serious AESIs  (as defined in Section  8.4), will be 
followed until resolution, stabiliz ation , until the event is otherwise explained, or the patient  is 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 62 of 98 12 Dec 2022 lost to follow -up (as defined in Section  7.3). Further information on follow -up procedures is 
given in  Appendix  3 (Section  10.3). 
8.4.4 Regulatory Reporting Requirements for Serious Adverse Event  
Prompt  notif ication (within 24  hours, see Appendix  3 [Section  10.3]) by the Investigator to the 
Sponsor  of an SAE is essential so that legal obligations and ethical responsibilities towards the 
safety of patient s and the safety of a study intervention  under clinical investigation are met.  
The Sponsor  has a legal responsibility to notify both the local regulatory a uthority and other 
regulatory agencies about the safety of a study intervention  under clinical investigation.  The 
Sponsor  will comply with country -specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRB, and Investiga tors. 
An Investigator  who receives an Investigator Safety Report describing an SAE or other specific 
safety information (e.g., summary or listing of SAEs) from the Sponsor will review and then file 
it along with the IB and will notify the IRB, if appropriate according to local requirements.  
Investigator  safety reports must be prepared for SUSAR s according to local regulatory 
requirements and forwarded to Investigators as necessary.  
8.4.5 Pregnancy  
Details of all pregnancies i n female patients and , if indicated , partners of male patient s will be 
collected after the start of study intervention  and until time period for reporting pregnancies 
should align with the time period for post -intervention contraception determined in Secti on 5.1. 
If a pregnancy is reported , the Investigator will record pregnancy information on the appropriate 
form and submit it to the Sponsor  within 24 hours of learning of the female patient s or partner of 
male patient  (after obtaining the necessary signed informed consent from the partner) pregnancy 
and should follow the procedures outlined in Appendix  4 (Section  10.4). 
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
Abnormal pregnancy outcomes ( e.g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered to be SAE s and will be reported as such . 
The patient/pregnant partner will be followed to determine the outcome of the pregnancy. The 
Investigator will collect follow -up information on the patient /pregnant partner and the neonate 
and the information will be forwarded to the Sponsor.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 63 of 98 12 Dec 2022 Any post -study pregnancy -related SAE considered reasonably related to the study intervention 
by the Investigator will be reported to the Sponsor as described in Section  8.4.4 . While the 
Investigator is not obligated to actively seek this information in former study patient s/pregnant 
partner s, he or she may learn of an SAE through spontaneous reporting.  
Any female pa tient who becomes pregnant while participating in the study will discontinue study 
intervention or be withdrawn from the study . 
Prior to continuation of study intervention following pregnancy, the following must occur:  
a. The Sponsor and the relevant IRB give writ ten approval.  
b. The patient  gives signed informed consent.  
c. The Investigator agrees to monitor the outcome  of the pregnancy and the status of the 
patient  and her offspring.  
8.4.6 Adverse event s of Special Interest  
An AESI  (serious or non -serious) is one of scientific and medical concern specific to the 
Sponsor’s product or program, for which ongoing monitoring and rapid communication by the 
Investigator to the Sponsor can be appropriate. Such an event might warrant further  investigation 
to characterize and understand it. Depending on the nature of the event, rapid communication by 
the Sponsor to other parties might also be warranted . 
AESIs are required to be reported by the Investigator to the Sponsor immediately (i.e., wit hin 
24 hours after learning of the event) regardless of their causality to the study treatment. The most 
appropriate diagnosis or if a diagnosis cannot be established, the abnormal laboratory values 
should be recorded on the eCRF and reported to the Sponso r immediately (i.e., within 24  hours 
after learning of the event), either as a SAE or an AESI.  Based on CDK4/6 inhibition mechanism 
of action, the following AEs will be defined as AESIs:  
• Myelosuppression: Hematology including monitoring for neutropenia, l eucopoenia,  
thrombocytopenia, and increased tendency to bleed  
• Embryo -fetal toxicity: highly effective methods of contraception will be used by the patients 
until 21 days after receiving the study drug  
• Interstitial lung disease: Pulmonary symptoms (dyspnea, pyrexia, and cough)  
• Gastrointestinal toxicity: e.g., diarrhea , nausea, vomiting, and abdominal pain  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 64 of 98 12 Dec 2022 8.5 Pharmacokinetics  
8.5.1 Blood Sample Collection  
Blood s amples  will be used to evaluate the PK of TCK -276. Each plasma  sample will be divided 
into 4 aliquots (1 each for the PK, the possible future metabolite assessments , a backup  for the 
PK, and a backup for the possible future metabolite assessments ). Samples collected for analyses 
of TCK -276 plasma  concentration may also be used to evaluate safety or efficacy aspects that 
address concerns ar ising during or after the study . 
Genetic analy ses will not be performed on these plasma  samples. Patient confidentiality  will be 
maintained.  At visits during which samples for the determination of plasma  concentration of 
TCK -276 will be taken , 1 blood draw of sufficient volume can be used.  
Intervention  concentration information that may unblind the study will not be reported to 
investigative sites or blinded personnel until the study has been unblinded.  
Any changes  in the timing or addition of timepoints for any planned study assess ments must be 
documented and approved by the relevant study team member and then archived in the Sponsor 
and site study files but will not constitute a protocol amendment. The IRB will be informed of 
any safety issues that require alteration of the safety monitoring scheme or amendment of the 
ICF. 
8.5.2 Urine Sample Collection  
Urine samples for the analysis of TCK -276 will be collected at the timepoints detailed in the S oA 
(Table  1-1). Urine will be collected at the following time intervals relative to study drug dosing: 
0 to 6 hours, 6 to 12 hours, 12 to 24 hours after dosing on Day  1, and from 0 (pre -dose) to 6, 6 to 
12, 12 to 24, 24 to 48, and 48 to 72 hours after dosing on Day  7. Urine sample collection, 
processing and shipping details will be outlined in a separate laboratory manual. In brief, urine 
will be processed and analyzed by a validated method for concentration s of TCK -276. The PK 
parameters listed in Section  3 will be calculated from the urine concentration  and volume of 
urine collected in each urine collec tion interval.  
8.6 Exploratory Assessments  
The f ollowing disease activity parameters  will be evaluated in this study;  
• ACR 20/50/70 1991 revised criteria for the classification of global functional status in RA on 
Days 1 and  7 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 65 of 98 12 Dec 2022 • DAS28, CDAI, SDAI scores on Days 1 and  7  
8.7 Genetics  
A blood sample  for DNA isolation will be collected from patients who have consented to 
participate in the optional pharmacogenomics component of the study. Patient s who do not wish 
to participate in the ge netic research may still participate in the study.  
In the event of DNA extraction failure, a replacement pharmacogenomic blood sample may be 
requested from the patient . Signed informed consent will be required to obtain a replacement 
sample.  
The final disposition of samples will be conducted per local regulations . 
See Appendix  5 (Section 10.5) for information regarding genetic research. Details on processes 
for collection  and shipment of these samples can be found in a separate laboratory manual . 
8.8 Biomarkers  
Following b iomarkers will be  evaluated by the central laboratories in this study ; 
MMP -3, granulocyte macrophage colony -stimulating factor  (GM-CSF), C-X-C motif chemokine 
ligand  10 (CXCL10 ), C-C motif chemokine ligand 2  (CCL2 ), cartilage oligomeric matrix protein  
(COMP ), tumor necrosis factor  (TNF )-α, TNF -RI, and interleukin ( IL)-6 . 
8.9 Health Economic s 
Health economics are not evaluated in this study.  
9 Statistical Consideration s 
Before database lock, a statistical analysis plan (SAP) will be issued as a separate document, 
providing detailed methods for the analyses outlined below. Any deviations from the planned 
analyses will be described and justified in the clinical study report  (CSR ). 
9.1 Statistical Hypotheses  
Not applicable . 
9.2 Analysis Populations  
For purposes of analysis, the following analysis populations  are defined:  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 67 of 98 12 Dec 2022 Patient discontinuations will be listed including the date of study exit, duration of treatment and 
reason for discontinuation. A listing of informed consent response will also be presented.  
A randomizati on listing will be presented and include the following: each patient’s 
randomization number, site, the treatment to which the patient has been randomized.  
9.3.1.3  Demographic and Anthropometric Information and Baseline Characteristics  
Demographic and anthropometri c variables (age, sex, ethnicity, race, height, weight, and BMI ) 
and disease activity data (ACR20/50/70, DAS28, CDAI, and SDAI ) will be listed by patient. 
Demographic characteristics (age, sex, ethnicity, and race) , anthropometric characteristics 
(height, weight, and BMI) and disease activity data (ACR20/50/70, DAS28, CDAI, and SDAI) 
will be summarized by cohort, treatment and for all patients in the safety analysis population .  
Medical history data will be listed by  patient including visit, description of the 
disease/procedure, Medical Dictionary for Regulatory Activities  (MedDRA ) System Organ Class 
(SOC), MedDRA preferred term (PT), start date, and stop date (or ongoing if applicable).  
9.3.2 Primary Endpoint(s)  Analysis  
9.3.2.1  Prior and Concomitant Medication  
Prior medications are those that started and stopped prior to the first dose of study drug. 
Concomitant medications are those taken after first dosing (including medications that started 
prior to dosing and continued after).  
Prior and concomitant medication will be listed by patient and will include the following 
information: reported name, PT, the route of administration, dose, frequency, start date/time, 
duration, and indication.  
Prior and concomitant medication will be cod ed according to the World Health Organization 
Drug Dictionary (WHO -DD) latest version.  
9.3.2.2  Exposure  
A listing of drug administration will be created and will include the date and time of 
administration.  
9.3.2.3  Adverse Events  
All AEs will be listed and coded accordin g to the MedDRA. Adverse events will be individually 
listed per patient number, presenting assigned treatment, verbatim term, Primary SOC, PT, 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 68 of 98 12 Dec 2022 treatment emergence (yes or no), date and time of onset, date and time of last study drug 
administration before A E, duration, time from onset since last study drug administration, 
frequency, severity and seriousness, relationship to study drug, the required action taken, 
outcome , if it is a reason for drop out , and if it is AESI or not . The treatment emergent AEs wil l 
be summarized by MedDRA terms and treatment groups. It will include evaluation of the 
number of AEs and the number of patients reporting these AEs.  
SAEs will be listed separately.  
9.3.2.4  Clinical Laboratory Tests  
A by -patient listing will be presented.  Clinical  laboratory tests (observed values  and change from 
baseline ) will be summarized descriptively in tabular format. Shift tables will be presented for 
select laboratory parameters.  
9.3.2.5  Vital Signs  
A by -patient listing will be presented. Observed values as well as change from baseline data will 
be summarized descriptively in tabular format.  
9.3.2.6  Standard 12 -lead Electrocardiogram  
Standard 12 -lead ECG data (observed and change from baseline) will be listed for each patient 
and time point. Observed values and change from baseline will be summarized descriptively in 
tabular format. A categorical QTc analysis will also be performed.  
9.3.2.7  Telemetry  
Cardiac  telemetry (real -time assessment) will assess the cardiac safety.  A by -patient listing will 
be provided.  
9.3.2.8  Physical Examination  
Abnormal physical examination findings will be listed.  
9.3.3 Secondary Endpoint(s)  Analysis  
9.3.3.1  Pharmacokinetics Analyses  
Plasma concentrations of TCK -276 and TEI -W00595  will be listed and summarized by 
descriptive statistics and displayed graphically as appropriate.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 69 of 98 12 Dec 2022 Plasma PK parameters of TCK -276 and TEI -W00595 will be calculated using non -
compartmental methods and tables, fi gures, and listings for PK parameters will be generated 
using PK population, as detailed in SAP.  
Plasma metabolite (TEI -W00595) to parent (TCK -276) molar ratio based on C max and AUC will 
be determined and summarized after first and last dose administration . Molar ratios will be 
calculated based on molecular weight of  for TCK -276 and  for TEI -W00595 . 
Urine PK parameters of TCK -276 will be listed and summarized as detailed in SAP.  
Dose proportionality will be assessed using power model based on Days 1 and 7 C max and 
AUC tau values for TCK -276.  
Further details of analysis of PK data will be provided in the SAP before database lock . 
9.3.4 Other Analy ses 
Not Applicable . 
9.3.4.1  Exploratory  Analyses  
Exploratory assessment  data will be listed and summarized by desc riptive statistics and displayed 
graphically as appropriate.  
9.4 Sample Size Determination  
Formal  sample size calculations were not performed. Thirty -two patients were chosen based on 
feasibility and are considered sufficient to meet the study objectives of this exploratory study.  

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 70 of 98 12 Dec 2022 10 Supporting Documentation and Operational Considerations  
10.1 Appendix  1: Regulatory , Ethical, and Study Oversight Considerations  
10.1.1  Regulatory  and Ethical Considerations  
This study will be conducted in accordance with the protocol and with:  
o Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) international ethical guidelines . 
o Applicable International C ouncil for Harmonisation  (ICH) Good Clinical Practice (GCP) 
guidelines . 
o Applicable laws and regulations . 
The protocol, protocol amendments, ICF, I B, and other relevant documents ( e.g., advertisements) 
must be submitted to an IRB by the Investigator and rev iewed and approved by the IRB  before 
the study is initiated.  
Any amendments to the protocol will require IRB approval before implementation of changes 
made to the study design, except for changes necessary to eliminate an immediat e hazard to 
study patient s. 
Protocols and any substantial amendments to the protocol will require health authority approval 
prior to initiation except for changes necessary to eliminate an immediate hazard to study 
patient s. 
The Investigator will be responsible for the following:  
o Providing written summaries of the status of the study to the IRB annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB/EC . 
o Notifying the IRB of SAE or other significant safety findings as required by IRB 
procedures . 
o Overall conduct of the study at the site and adherence to requirements of 21 Code of 
Federal Regulations  (CFR ), ICH  GCP  guidelines, the IRB, and all other applicable local 
regulations . 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 71 of 98 12 Dec 2022 10.1.2  Financial Disclosure  
Investigators and sub -Investigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate regulatory  authorities. 
Investigators are responsible for providing information on financial interests during the course of 
the study and for 1 year after completion of the study.  
10.1.3  Informed Consent Process  
The Investigator or their representative will explain the natur e of the study , including the risks 
and benefits,  to the patient  or the patient ’s LAR  and answer all  questions regarding the study.  
Patients must be informed that their participation is voluntary. Pa tients or the patient ’s LAR  will 
be required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy , and data protection  requirements, where applicable, 
and the IRB or study center.  
The medical record must include a statement that written informed consent was obtained before 
the patient  was enrolled in the study and the date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.  
Patient s must be re -consented  to the most current version of the ICF(s) during th eir participation 
in the study.  
A copy of the ICF(s) must be provided to the patient  or the patient ’s LAR . 
A patient who is rescreened is required to sign a new ICF as a new assigned patient number.  
If a pro tocol amendment is required, the ICF may need to be revised to reflect the changes to the 
protocol. If the ICF is revised, it must be reviewed and approved by the appropriate IRB and  
signed by all patient s subsequently enrolled in the study as well as those currently enrolled in the 
study.  
10.1.4  Data Protection  
Patients will be assigned a unique identifier by the Sponsor. Any patient  records or datasets that 
are transferred to the Sponsor will contain the identifier only; patient  names or any information 
which would make the patient  identi fiable will not be transferred.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 72 of 98 12 Dec 2022 The p atient  must be informed that their personal study -related da ta will be used by the Sponsor 
in accordance with local data protection law. The level of disclosure must also b e explained to 
the patient  who will be required to give consent for their data to be used as described in the 
informed consent . 
The patient  must  be informed that their medical records may be examined by Clinical Quality 
Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate IRB 
members, and by inspectors from regulatory  authorities.  
10.1.5  Committees Structure  
The SRC w ill consist of the following core members:  
• Principal  Investigator s 
• Medical  Monitor  
• Sponsor  Medical Representative  
The SRC may also request to have attendance of or off -line support and input from the following 
functions as required:  
• Study  and Sponsor Statisticians  
• Sponsor and/or study Medical Specialists (e.g., Neurologist, ECG Cent er cardiologists, etc.)  
• Study and Sponsor Pharmacokineticists  
10.1.6  Dissemination of Clinical Study Data  
A summary of the results of the clinical study  together with  a summary that is understandable to 
a layperson will be provided after the global end (or early termination) of the study  in all 
countries concerned to ensure full availability of all clinical data under this protocol, within 
12 months.  
10.1.7  Data Quality Assur ance  
All patient  data relating to the study will be recorded on printed or electronic case report forms 
(eCRFs) unless transmitted to the Sponsor or designee electronically ( e.g., laboratory data). The 
Investigator is responsible for verifying that data en tries are accurate and correct by physically or 
electronically signing t he CRF.  
Guidance on completion of eCRFs will be provided in eCRF Completion Instructions.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 73 of 98 12 Dec 2022 The Investigator must permit study -related monitoring, audits, IRB review, and Regulatory  
Agency inspections and provide direct a ccess to source data documents.  
Monitoring details describing strategies, including definition of study critical data items and 
processes (e.g., risk -based initiatives in operations and quality such as risk management and 
mitigation strategies and analytical risk -based monitoring), methods, responsibilities and 
requirements, including handling of noncompliance issues and monitoring tec hniques (central, 
remote, or on -site monitoring) are provided in the monitoring plan.  
The Sponsor or designee is responsible for the data management of this study including quality 
checking of the data.  
The Sponsor assumes accountability for actions delega ted to other individuals ( e.g., CROs ). 
Records and documents, including signed ICF, pertaining to the conduct of this study must be 
retained by the Investigator for 2 years  after study completion unless local regulations or 
institutional policies require a  longer retention period. No records may be destroyed during the 
retention period without the written approval of the Sponsor. No records may be transferred to 
another location or party without written notification to the Sponsor.  
All data generated by the  site personnel will be captured electronically at each study center using 
eCRFs. Data from external sources (such as laboratory data) will be imported into the database. 
Once the eCRF clinical data have been submitted to the central server at the independ ent data 
center, corrections to the data fields will be captured in an audit trail. The reason for change, the 
name of the person who performed the change, together with the time and date will be logged to 
provide an audit trail.  
If additional corrections are needed, the responsible monitor or data manager will raise a query in 
the electronic data capture (EDC) application. The appropriate staff at the study site will answer 
queries sent to the Investigator. The name of the staff member responding to the qu ery, and time 
and date stamp will be captured to provide an audit trail. Once all source data verification is 
complete and all queries are closed, the monitor will freeze the eCRF page.  
The specific procedures to be used for data entry and query resolution using the EDC 
system/eCRF will be provided to study sites in a training manual. In addition, site personnel will 
receive training on the EDC system/eCRF.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 74 of 98 12 Dec 2022 10.1.8  Source Documents  
Source  documents provide evidence for the existence of the patient  and substantiate the integrity  
of the data collected. Source documents are filed at the Investigator’s site.  
Data reported in the eCRF that are transcribed from source documents must be consistent with 
the source documents or the discrepancies must be exp lained. The Investigator may need to 
request previous medical records or transfer records, depending on the study. Also, current 
medical records must be available.  
The Investigator must maintain accurate documentation (source data) that supports the 
inform ation entered in the eCRF.  
Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of patients are being protected; and that the study is being 
conducted in accordance with the currently approved protocol and any other study agreements, 
ICH GCP, and all applicable regulatory requirements.  
10.1.9  Study and Site Start and Closure  
First Act of Recruitmen t 
The study start date is the date on which the clinical study will be open for recruitment of 
patient s. 
The first act of recruitment is  considered when the first site is activated and allowed to screen 
patients, which will be the study start date . 
Study/S ite Termination  
The Sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study  site closure visit has been performed.  
The Investigator may initiate study  site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 75 of 98 12 Dec 2022 Reasons for the early closure of a study site by the Sponsor or Investigator may include but are 
not limited to:  
For study termination:  
• Discontinuation  of further study intervention development . 
For site termination:  
• Failure of the Investigator to comply with the protocol, the requirements of the IRB or local 
health authorities, the Sponsor's procedures, or GCP guidelines . 
• Inadequate or no recruitment (evaluated after a reasonable amount of time) of patient s by the 
Investigator . 
• Total number of patient s included earlier than expected.  
If the study is prematurely terminated or suspended, the Sponsor  shall promptly inform the 
Investigators, the IRBs, the regulatory  authorities, and any contract research organization(s) used  
in the study of the reason for termination or suspension, as specified by the applicable regulatory  
requirements. The Investigator shall promptly inform the patient  and should assure appropriate 
patient  therapy and/or follow -up. 
10.1.10  Publication Policy  
The res ults of this study may be published or presented at scientific meetings  after study 
completion. Before any data from this study are published on the initiative of the Investigator, 
the Investigator must  obtain written approval  from the Sponsor . If this is foreseen, the 
Investigator agrees to submit all manuscripts or abstracts to the Sponsor at least 60  days prior to  
submission. This allows the Sponsor to protect proprietary information and to provide comments.  
The Sponsor will comply with the requirements for publication of study results. In accordance 
with standard editorial and ethical practice, the Sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site d ata. In this case, a 
coordinating I nvestigator will be designated by mutual agreement.  
Authorship will be determined by mutual agreement and in line with International Committee of 
Medical Journal Editors authorship requirements.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 76 of 98 12 Dec 2022 10.1.11  Protocol Approval and Amen dment  
Before the start of the study, the study protocol and/or other relevant documents will be approved 
by the IRB/Competent Authorities, in accordance with local legal  requirements. The Sponsor 
must ensure that all ethical and legal  requirements have bee n met before the first patient is 
enrolled in the study.  
This protocol is to be followed exactly. To alter the protocol, amendments must be written, 
receive approval from the appropriate personnel, and receive IRB/Competent Authority approval 
prior to impl ementation (if appropriate). In the US A: Following approval, the protocol 
amendment(s) will be submitted to the Investigational new drug  (IND) under which the study is 
being conducted.  
Administrative changes (not affecting the patient benefit/risk ratio) m ay be made without the 
need for a formal amendment. All amendments will be distributed to all protocol recipients, with 
appropriate instructions.  
10.1.11.1  Access to Source Data  
During the study, a monitor will make site visits to review protocol compliance, compare  eCRF 
entries and individual patient ’s medical records, assess drug accountability, and ensure that the 
study is being conducted according to pertinent regulatory  requirements. eCRF entries will be 
verified with source documentation. The review of medical records will be performed in a 
manner to ensure that patient  confidentiality is maintained.  
Checking of the eCRF entries for completeness and clarity, and cross -checking with source 
documents, will be required to monitor the progress of the study. Moreover , regulatory  
authorities of certain countries, IRBs, and/or the Sponsor’s Clinical Q A Group may wish to carry 
out such source data checks and/or on -site audit inspections. Direct access to source data will be 
required for these inspections and audits; they will be carried out giving due consideration to 
data protection and medical confiden tiality. The Investigator assures the Sponsor , and   if 
involved in monitoring/data management,  of the necessary support at all times.  
  

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 77 of 98 12 Dec 2022 10.2 Appendix  2: Clinical Laboratory Tests  
The tests detailed in Table  10–1 will be performed by each local  laboratory (for assessments of 
Screening and Day -1) and central laboratory  (for assessments from Day  1 to last visit) . Note that 
erythrocyte sedimentation rate (ESR) is not included in Table  10–1, and it will be assessed at 
local laboratory  as part of d isease activity data on Days 1 and 7 , not as safety laboratory test . 
Local laboratory results are only required in the event that the central laboratory results are not 
available in time for either study intervention administration and/or response evaluation. If a 
local sample is required, it is impo rtant that the sample for central analysis is obtained at the 
same time.  Additionally, if the local laboratory results are used to make either a study 
intervention decision or response evaluation, the results must be recorded . 
Protocol -specific requirement s for inclusion or exclusion of patient s are detailed in Section  5 of 
the protocol.  
Additional tests may be performed at any time during the study as determined necessary by the 
Investigator or required by local regulations . 
Investigators must document their review of each laboratory safety report.  
Table  10–1 Protocol -required Safety Laboratory Tests  
Hematology  
White blood cell (WBC) count  Neutrophils (percentage and absolute count)  
Red blood cell (RBC) count  Lymphocytes (percentage and absolute count)  
Hemoglobin (Hb)  Monocytes (percentage and absolute count)  
Hematocrit (HCT)  Eosinophils (percentage and absolute count)  
Mean corpuscular volume (MCV)  Basophils (percentage and absolute count)  
Mean corpuscular hemoglobin (MCH)  Platelet count  
Mean corpuscular hemoglobin concentration (MCHC)  
Reticulocytes (count and percentage)  RBC distribution width  
Coagulation  
Prothrombin time  International Normalized Ratio (INR)  
Activated partial thromboplastin time (aPTT)   
Clinical Chemistry  
Alanine aminotransferase (ALT)  Gamma glutamyl transferase (GGT)  
Albumin  Glucose  
Alkaline phosphatase (ALP)  Lactate dehydrogenase (LDH)  
Aspartate aminotransferase (AST)  Phosphorus  
Blood urea nitrogen (BUN)  Potassium  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 78 of 98 12 Dec 2022 Calcium  Sodium  
Chloride  Total bilirubin  
Total c holesterol  Total protein  
Creatinine  Triglycerides  
Creatine kinase (CK)  C- reactive protein (CRP)  
Follicle stimulating hormone (FSH) (Screening Visit only; Post -menopausal females only)  
Urinalysis  
Bilirubin  Blood  
Glucose  pH and specific gravity  
Ketones  Protein  
Leukocytes  Urobilinogen  
Nitrite  Color and appearance  
Microscopic (only for abnormal urine stick test 
findings) -Hyaline casts, cellular casts, granular casts,  
RBC and WBC  Urinary creatinine (to exclude dilution effect)  
Viral Serology  
Hepatitis B core antibody (anti -HBc)  Human immunodeficiency virus (HIV)  
(Types 1 and 2) antibodies  Anti-hepatitis B surface antigen (HBsAg)  
Hepatitis C virus antibody (anti -HCV)   
COVID -19 Testing  
Severe acute respiratory syndrome coronavirus 2  (SARS -CoV -2) reverse transcription polymerase chain reaction 
(RT-PCR ) 
Urine Drug Screening, Cotinine Test, and Alcohol Test  
Amphetamines  Cocaine  
Barbiturates  Opiates  
Benzodiazepines  Phencyclidine  
Oxycodone  3,4-methylenedioxymethamphetamine ( MDMA ) 
Tricyclic Antidepressants  Propoxyphene  
Cannabinoids  Cotinine  
Alcohol/Ethanol (to be tested using breathalyzer)  
Pregnancy Testing  
Urine human beta chorionic gonadotrophin  
 
  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 84 of 98 12 Dec 2022 learns of the event. Additional follow -up (cause of death, autopsy report, and hospital report) 
information s hould be reported within an additional 8 days (15  days total).  
If the SUSAR is not fatal or life -threatening but is otherwise serious, associated with study 
intervention, and unexpected, regulatory  authorities and IECs will be notified within 
15 calendar d ays after the Sponsor learns of the event.  
The Sponsor will notify the Investigators in a timely fashion of relevant information about 
SUSARs that could adversely aff ect the safety of patient s. Follow -up information may be 
submitted if necessary.  
The Sponsor will also provide annual safety updates to the regulatory  authori ties and I ECs 
responsible for the study. These updates will include information on SUSARs and other 
relevant safety findings.  
AE=adverse event; IEC= Institutional Review Board; SAE=serious adverse event ; SUSAR=suspected unexpected 
serious adverse reactions  
Serious Adverse Events  Contact Details  
SERIOUS ADVERSE EVENT REPORTING INSTRUCTIONS  
 
 
 
(See SAE Reporting Instructions)  
 
 
 
1. Telephone the  to inform him/her  that you are emailing/ faxing a 
SAE form. If the  is not available or you are calling after business 
hours (8:30 am to 5:30 pm Eastern time, Monday to Friday), leave a message in their voice 
mailbox.  
2. Provide the  with the Principal Investigator’s name, your name, the 
telephone number whe re you can be reached, and the protocol number and title.  
3. Email/ Fax the SAE form and any supporting documentation to the  
within 24  hours of becoming aware of the event.  
4. After business hours, the  may be reached through  
24-hour answering service at . Give the answering service the protocol 
number, the study intervention name, and the Sponsoring pharmaceutical company.  

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 85 of 98 12 Dec 2022 10.4 Appendix  4: Contraceptive and Barrier Guidance  
10.4.1  Definitions  
Women of Childbearing Potential  (WOCB P) 
A woman is considered fertile following menarche and until becoming post -menopausal unless 
permanently sterile (see below).  
Women in the following categories are not considered to be a woman of childbearing potential:  
1. Premen archal  
2. Premenopausal female with one of the following:  
• Documented hysterectomy   
• Documented bilateral salpingectomy  
• Documented tubal ligation  
• Documented bilateral oophorectomy  
Note: Documentation can come from the site personnel’s review of the patient’s medical records, 
medical examination, or medical history interview.  
3. Post-menopausal female  
• A post -menopausal state is defined as no menses for 12  months without an alternative 
medical cause. A high FSH level in the post -menopausal range (>  40 U/mL) may be used to 
confirm a post -menopausal state in women not using hormonal contraception or hormonal 
replacement therapy (HRT). However, in the absence of 12  months of amenorrhea, a s ingle 
FSH measurement is insufficient.  
10.4.2  Contraception Guidance  
Male pa tients  
Male patient s with female partners of childbearing potential (including partners who are pregnant 
or breastfeeding [including pumping breast milk to feed to a child]) must use contraception if 
any of the following criteria are met:  
• Genotoxic study medication  
• Study medication where reproductive toxicology studies have not yet been conducted  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 86 of 98 12 Dec 2022 • Study medication with demonstrated or suspected human teratogenicity/fetotoxicity at 
subth erapeutic exposure levels if relevant systemic concentrations may be achieved in 
WOCBP from exposure to seminal fluid  
Male pa tients  with female partners of childbearing potential are eligible to participate if they 
agree to ONE of the following during the protocol -defined time frame : 
• Are abstinent from penile -vaginal intercourse as their usual and preferred lifestyle (abstinent 
on a l ong term and persistent basis) and agree to remain abstinent.  
• Agree to use a male condom plus partner use of a contraceptive method with a failure rate of 
< 1% per year as described in the table below when having penile -vaginal intercourse with a 
WOCBP who  is not currently pregnant.  
• Agree to use a male condom when having penile -vaginal intercourse WOCBP who is 
currently pregnant.  
In addition , male pa tients must refrain from donating sperm for the duration of the study and for 
3 months  after the final dose o f study medication.  
Male pa tients with a pregnant or breastfeeding (including pumping breast milk to feed to a child) 
partner must agree to remain abstinent from penile vaginal intercourse or use a male condom 
during each episode of penile penetration duri ng the study and for at least 3 months  after the 
final dose of study medication.  
Female pa tients  
Female pa tients  of childbearing potential are eligible to participate if they agree to use a highly 
effective method of contraception consistently and correctly as described in the table below. If 
the Investigator has another method not listed below but is proven to have  a failure rate <  1%, 
then this method may be considered after discussion with the Medical Monitor or Sponsor study 
physician.  
Highly Effective Contraceptive Methods  
Highly Effective Contraceptive Methods That Are User Dependent  
• Failure rate of <  1% per ye ar when used consistently and correctly.  
• Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation  
o Oral 
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 87 of 98 12 Dec 2022 o Intravaginal  
o Transdermal  
• Progestogen only hormonal contraception associated with inhibition of ovulation  
o Oral 
o Injectable  
Highly Effective Methods That Are User Independent  
• Implantable progestogen only hormonal contraception associated with inhibition of 
ovulation : 
o Intrauterine device (IUD)  
o Intrauterine hormone -releasing system (IUS)  
o Bilateral tubal occlusion  
Vasectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirm ed. If not, 
an additional highly effective method of contraception should be used.  
Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk asso ciated with the study medication. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the pa tient. 
• Women of childbearing potential should only be included after a conf irmed menstrual period 
and a negative highly sensitive serum pregnancy test.  
• Additional urine pregnancy testing should be performed at monthly intervals during the 
treatment period and at End of Treatment/End of Study, after the final dose of study 
medicat ion and as required locally.  
• Pregnancy testing will be performed when pregnancy is suspected  
• Pregnancy testing will be performed at Screening and at every post -Screening visit before 
study medication application.  
• If a study p atient  is pregnant and stays in  the study for observation no pregnancy testing will 
be performed as long as the pregnancy lasts.  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 88 of 98 12 Dec 2022 10.4.2.1  Collection of Pregnancy Information  
Male Patient s with Female Partners Who Become Pregnant  
• The Investigator will attempt to collect pregnancy information on any male patient’s female 
partner who becomes pregnant while the male patient is in this study. This applies only to 
male patients who receive the study drug. If the study patient is later f ound to be on placebo, 
then pregnancy data collection can stop.  
• After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the Investigator will record pregnancy information on the appropriate form and 
submit it to the  Sponsor within 24 hours of learning of the partner’s pregnancy. The female 
partner will also be followed to determine the outcome of the pregnancy. Information on the 
status of the mother and child will be forwarded to the Sponsor. Generally, the follow -up will 
not be required after birth of the child or elective termination of pregnancy. Any termination 
of the pregnancy will be reported regardless of fetal status (presence or absence of 
anomalies) or indication for the procedure.  
Female Patient s Who Becom e Pregnant  
• The Investigator will collect pregnancy information on any female patient who becomes 
pregnant while participating in this study. This applies only to female patients who receive 
the study drug. If the study patient is later found to be on place bo, then pregnancy data 
collection can stop. Information will be recorded on the appropriate form  and submitted to 
the Sponsor within 24  hours of learning of a patient’s pregnancy. The patient will be 
followed to determine the outcome of the pregnancy. The  Investigator will collect any 
follow -up information on the patient and the neonate, and the information will be forwarded 
to the Sponsor. Generally, follow -up will not be required after birth of the child or elective 
termination of pregnancy. Any terminat ion of the pregnancy will be reported, regardless of 
fetal state (presence or absence of anomalies) or indication for the procedure.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregna ncy will be reported as an AE or SAE. A spontaneous 
abortion is always considered to be an SAE and will be reported as such. Any post -study 
pregnancy -related SAE considered reasonably related to study drugs by the Investigator will 
be reported to the Spons or as described in Section  8.4.4 . While the Investigator is not 
obligated to actively seek this information in former study patients, he or she may learn of an 
SAE through spontaneous reporting.  
• Any female patient who becomes pregnant while participating in the study will discontinue 
the study drugs and will be withdrawn from the study.   
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 89 of 98 12 Dec 2022 10.5 Appendix  5: Genet ics 
Use/Analysis of DNA  
Genetic variation may impact a patient ’s response to therapy. Variable response to therapy ma y 
be due to genetic determinants that impact intervention  absorption, distribution, metabolism, and 
excretion; mechanism of action of the intervention ; disease etiology; and/or molecular subtype of 
the disease being treated. Therefore, where local regulations  and IRB allow, a blood  sample will 
be collected for DNA analysis.  
DNA samples will be used for research related to TCK -276 or RA and related disea ses. They 
may also be used to develop tests/assays related to study intervention and/or interventions of this 
drug class  and RA. Genetic  research may consist of the analysis of one or more candidate genes 
or the analysis of genetic markers throughout  the g enome or analysis of the entire genome (as 
appropriate) in relation to TCK -276 (as appropriate).  
The samples may be analyzed  as part of a multi -study assessment of genetic factors involved in 
the response  to TCK -276 or study intervention of this class to u nderstand the study disease or 
related conditions.  
The results of genetic analy ses may be reported in the CSR or in a separate study summary . 
The Sponsor will store the DNA samples in a secure storage space with adequate measures to 
protect confidentiality.   
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 90 of 98 12 Dec 2022 10.6  
 
 
 
 
 
 
Prohibited or cautioned medications may include, but are not limited to, those listed below. 
These listings of prohibited or cautioned concomitant treatments are not considered all inclusive.  

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 91 of 98 12 Dec 2022 

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 92 of 98 12 Dec 2022 

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 93 of 98 12 Dec 2022 

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 94 of 98 12 Dec 2022 10.7 Appendix  7: Abbreviations  and Definitions  
Abbreviations  Definition  
ACR American College of Rheumatology  
AE Adverse event  
AESI  Adverse event of special interest  
Ae Amount of study drug excreted unchanged in the urine  
ALT Alanine aminotransferase  
AST  Aspartate aminotransferase  
AUC  Area under the plasma concentration -time curve  
AUC 0-inf Area under the plasma concentration -time curve from pre -dose (time 0) 
extrapolated to infinite time (AUC last + Clast/λz) calculated using the 
linear -log trapezoidal rule  
AUC 0-t Area under the plasma concentration -time curve up to last measurable 
concentra tion  
AUC 0-24h Area under the plasma concentration -time curve up to 24 hours  
AUC tau Area under the plasma concentration -time curve over a dosing interval, 
tau = 24 hours  
  
BMI  Body mass index  
BP Blood pressure  
bpm Beats per minute  
CCL2 C-C motif chemokine ligand 2  
CDAI Clinical disease activity index  
CDK  Cyclin dependent kinase  
CFR  Code of Federal Regulations  
CL/F  Apparent total body clearance  
CL r Renal clearance  
Cmax Maximum plasma concentration determined directly from the 
concentration -time profile  
COMP  Cartilage oligomeric matrix protein  
COVID -19 Coronavirus disease 2019  
CRF Case report forms  
CRO  Contract research organization  
CSR  Clinical study report  

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 95 of 98 12 Dec 2022 Abbreviations  Definition  
CTCAE  Common Terminology Criteria for Adverse Event  
CycD D-type cyclins  
  
CXCL10  C-X-C motif chemokine ligand 10  
DAS28  Disease activity score  28 
DDI Drug -drug interaction  
DMARD  Disease modifying antirheumatic drug  
ECG  Electrocardiogram  
eCRF  Electronic case report form  
EDC Electronic data capture  
FSH Follicle stimulating hormone  
ESR Erythrocyte sedimentation rate  
GCP  Good Clinical Practice  
GM-CSF Granulocyte macrophage colony stimulating factor  
HBc Hepatitis B core  
HBsAg  Hepatitis B surface antigen  
HCV  Hepatitis C virus  
HIV Human immunodeficiency virus  
IB Investigator’s Brochure  
ICF Informed consent form  
ICH International Council for Harmonisation  
IGRA -TB Interferon gamma release assay for tuberculosis  
ILD Interstitial lung disease  
IL-6 Interleukin -6 
IMP Investigational medicinal product  
IRB Institutional Review Board  
LAR Legally authorized representative  
MAD  Multiple ascending dose  
  
MedDRA  Medical Dictionary for Regulatory Activities  
MMP -3 Matrix metalloproteinase -3 
MR Metabolic ratio  

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 96 of 98 12 Dec 2022 Abbreviations  Definition  
MRT last Mean residence time up to last measurable concentration  
MRT 0-inf Mean residence time extrapolated to infinity  
NOAEL  No observed adverse effect level  
  
  
OTC Over-the-counter  
PD Pharmacodynamics  
  
PK Pharmacokinetics  
PO By mouth  
PT Preferred term  
QD Once daily  
QTc QT interval corrected for heart rate  
QTcF  QT interval corrected for heart rate using Fridericia’s correction  
RA Rheumatoid arthritis  
RASF  Rheumatoid arthritis synovial fibroblasts  
Rb Retinoblastoma protein  
SAD  Single ascending dose  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SARS -CoV-2 Severe acute respiratory syndrome coronavirus 2  
SC Subcutaneous  
SDAI Simplified disease activity index  
SoA Schedule of Activities  
SOC  System Organ Class  
SOP Standard operating procedure  
SRC  Safety Review Committee  
SUSAR  Suspected unexpected serious adverse reactions  
tmax Time of maximum plasma concentration determined directly from the 
concentration -time profile  
TNF Tumor necrosis factor  
t½ Terminal elimination half -life calculated  

Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 97 of 98 12 Dec 2022 Abbreviations  Definition  
ULN  Upper limit of normal  
USA  United States of America  
WOCBP  Women of childbearing potential  
Teijin A merica, Inc.  Clinical Study Protocol  
TCK -276-102 CONFIDENTIAL  
 
Final ; Version 3.0 98 of 98 12 Dec 2022 11 References  
1. McInnes IB  and Schett G. The pathogenesis of rheumatoid arthritis. N Eng J Med. 2011; 
365(23): 2205 -2219 . 
2. Bottini N and Firestein GS. Duality of fibroblast -like Synoviocytes in RA: passive 
responders and imprinted aggressors. Nat Rev Rheumatol. 201 3;9(1):24-33. 
3. Okada Y , Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis 
contributes to biology and drug discovery. Nature. 2014:506(7488):376 -381. 
4. Sherr CJ  and Roberts JM. CDK inhibitors: positive and negative regulators of G1 -phase 
progression. Genes Dev. 1999;13 (12):1501 -1512.  
5. Nonomura Y , Kohsaka H, Nagasaka K, and Miyasaka N. Gene transfer of a cell cycle 
modulator exerts anti -inflammatory effects in the treatment of arthritis. J Immunol. 
2003;171 (9):4913 -4919.  
6. Nonomura Y , Nagasaka K, Hagiyama H, Sekine C, Nanki T, Tamamori -Adachi M, et al. 
Direct modulation of rheumatoid inflammatory mediator expression in retinoblastoma 
protein -dependent and -independent  pathways by cyclin -dependent kinase 4/6. Arthritis 
Rheum. 2006;54 (7):2074 -2083.  
7. Investigator's Brochure of TCK -276. Final Edition  2, . 
8. FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID -19 Public 
Health Emergency,  March 2020, Updated on January 27, 2021. 
https://www.fda.gov/regulatory -information/search -fda-guidance -documents/fda -guidance -
conduct -clinical -trials -medical -products -during -covid -19-public -health -emergency. Accessed 
05 August  2021.  
9. Aletaha D, Neogi T, S ilman AJ, Funovits J, Felson DT, Bingham lll CO, et al. 2010 
rheumatoid arthritis classification criteria: an  American College of Rheumatology/European 
League  Against Rheumatism collaborative initiative. Ann Rheum Dis 2010; 
69(9):1580 -1588.  
